<SEC-DOCUMENT>0000318154-24-000042.txt : 20241030
<SEC-HEADER>0000318154-24-000042.hdr.sgml : 20241030
<ACCEPTANCE-DATETIME>20241030160604
ACCESSION NUMBER:		0000318154-24-000042
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20241030
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241030
DATE AS OF CHANGE:		20241030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		241410289

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>amgn-20241030.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f792137b-fe40-436a-ac4b-fe11133d7e22,g:8da3bbc4-0fa2-4f60-a877-ef620ccf84e7,d:b7f80d7de99245f9bea627d42dba71d5-->
<html xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:amgn="http://www.amgen.com/20241030" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amgn-20241030</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-24">0000318154</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-25">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="amgn-20241030.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-30</xbrli:startDate><xbrli:endDate>2024-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-30</xbrli:startDate><xbrli:endDate>2024-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-30</xbrli:startDate><xbrli:endDate>2024-10-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib7f80d7de99245f9bea627d42dba71d5_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 OR 15(d) of</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported)</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">October&#160;30, 2024</ix:nonNumeric></span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;-</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Amgen Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.919%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37702</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">95-3540776</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">One Amgen Center Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Thousand Oaks</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">91320-1799</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">805</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">447-1000</ix:nonNumeric> </span></div><div style="margin-bottom:1.5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:32.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.643%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.336%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-17">Common stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-18">AMGN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-20">2.000% Senior Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-21">AMGN26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2). Emerging growth company&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-23">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:1.5pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><div id="ib7f80d7de99245f9bea627d42dba71d5_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 Results of Operations and Financial Condition.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Third Quarter 2024 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-26">October&#160;30, 2024</ix:nonNumeric>, the Company issued a press release announcing its unaudited results of operations for the three and nine months ended September 30, 2024, and its unaudited financial position as of September 30, 2024. The full text of the press release is furnished as Exhibit 99.1 hereto.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In its press release the Company included certain non-U.S. Generally Accepted Accounting Principles (GAAP) financial measures as defined in Regulation G promulgated by the Securities and Exchange Commission. The non-GAAP financial measures included in the press release are non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP operating expenses and sub-components of non-GAAP operating expenses such as non-GAAP cost of sales, non-GAAP research and development (R&amp;D) expenses and non-GAAP selling, general and administrative expenses. Reconciliations for such non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the press release. The Company included Free Cash Flow (FCF), which is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that this presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor&#8217;s overall understanding of the financial performance and prospects for the future of the Company&#8217;s ongoing business activities by facilitating comparisons of results of ongoing business operations among current, past and future periods. The Company believes that FCF provides a further measure of the Company&#8217;s liquidity. The Company uses non-GAAP financial measures in connection with its own budgeting and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the costs and other items excluded from the most directly comparable GAAP financial measures to calculate non-GAAP financial measures:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Acquisition-related expenses: Acquisition-related charges are primarily associated with assets acquired in connection with business acquisitions, including intangible assets and acquired inventory. Such charges include amortization of developed-product-technology rights, licensing rights, R&amp;D technology rights, marketing-related rights and step-up to fair value of acquired inventory, as well as net impairment charges of in-process R&amp;D assets. Net charges for purchased intangible assets are significantly impacted by the timing and magnitude of the Company&#8217;s acquisitions and potential product approvals as they relate to in-process R&amp;D projects acquired. Accordingly, these net charges may vary in amount from period to period. The Company excludes these net charges for purposes of calculating the non-GAAP financial measures presented to facilitate a more meaningful evaluation of the Company&#8217;s current operating performance and comparisons to past operating performance. The Company believes that excluding noncash net charges related to those intangible assets and inventory acquired in business acquisitions treats those assets as if the Company had developed them internally in the past and, thus, provides a supplemental measure of profitability in which these acquired assets are treated in a comparable manner to the Company's internally developed or produced assets.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Net charges pursuant to the Company&#8217;s restructuring and cost savings initiatives: Costs from restructuring and cost savings initiatives are primarily related to facilities charges, including asset impairments and accelerated depreciation, and severance and benefits for employees terminated pursuant to our transformation and process improvement efforts. Costs from such initiatives are inconsistent in amount and are significantly impacted by the timing and nature of these events. Therefore, although the Company may incur these types of expenses in the future, it believes that eliminating these charges for purposes of calculating the non-GAAP financial measures provides a supplemental evaluation of the Company&#8217;s current operating performance and facilitates comparisons to past operating performance.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Other items: The Company adjusts GAAP financial results for certain income and expenses (or gains and losses). These adjustments include: (1) gains and losses on our investments in equity securities; (2) certain items associated with judgments and/or settlements for legal proceedings discussed in our filings; and (3) (i) interest expense and income on senior notes issued in March 2023 and (ii) debt issuance costs and other fees related to our bridge credit agreement and term loan credit agreement, incurred prior to the closing of our acquisition of Horizon Therapeutics plc. The Company excludes these items for the purpose of calculating the non-GAAP financial measures presented because the Company believes these items are outside the ordinary course of business. The Company believes eliminating these items provides a supplemental evaluation of the Company&#8217;s current operating performance and facilitates comparisons to past operating performance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The tax effect of the adjustments between GAAP and non-GAAP results take into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Generally, the tax impact of adjustments, including the amortization of intangible assets and acquired inventory, gains and losses on our investments in equity securities and expenses related to restructuring and cost savings initiatives, depends on whether the amounts are deductible in the respective tax jurisdictions and the applicable tax rate(s) in those jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The press release also contains a discussion of the additional purposes for which the Company&#8217;s management uses these non-GAAP financial measures.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This information and the information contained in the press release shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report is not incorporated by reference into any filings of the Company made under the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing unless specifically stated so therein.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><div id="ib7f80d7de99245f9bea627d42dba71d5_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div style="margin-bottom:6pt;margin-top:4.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-bottom:6pt;margin-top:4.4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:7.602%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-20240930earningsrelea.htm">Press Release dated October 30, 2024</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><div id="ib7f80d7de99245f9bea627d42dba71d5_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.577%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEN INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-27">October 30, 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter H. Griffith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter H. Griffith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>amgn-20240930earningsrelea.htm
<DESCRIPTION>AMGN-2024.9.30 EARNINGS RELEASE
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6a02bf03f592475888125c063f2dc750_1"></div><div style="min-height:67.5pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:32.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.864%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><img alt="amgenlogo.jpg" src="amgenlogo.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:175px"></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:100%">News Release</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:100%">One Amgen Center Drive<br>Thousand Oaks, CA 91320-1799<br>Telephone 805-447-1000<br>www.amgen.com</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div id="i6a02bf03f592475888125c063f2dc750_4"></div><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:16pt;font-weight:700;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THOUSAND OAKS, Calif. (Oct. 30, 2024) - Amgen (NASDAQ&#58;AMGN) today announced financial results for the third quarter of 2024.</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Strong growth in sales and earnings this quarter reflects the momentum we're building throughout our business. We continue to invest heavily in our rapidly advancing pipeline, with a focus on delivering innovative therapies across our core therapeutic areas,&#8221; said Robert A. Bradway, chairman and chief executive officer.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Key results include&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">For the third quarter, total revenues increased 23% to $8.5 billion in comparison to the third quarter of 2023.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.9pt">Produ</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ct sales grew </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24%</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, driven by 29% volume growth, partially offset by 2% lower net selling price. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Excluding sales from our Horizon Therapeutics (Horizon) acquisition, product sales grew 8%, driven by volume growth of 12%.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.9pt">Ten products delivered at least double-digit sales growth in the third quarter, including Repatha</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (evolocumab), TEZSPIRE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (tezepelumab-ekko), BLINCYTO</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (blinatumomab), EVENITY</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (romosozumab-aqqg), and TAVNEOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(avacopan).</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Our performance included $1.2 billion of sales from our rare disease products, driven by several first-in-class, early-in-lifecycle medicines, including TEPEZZA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (teprotumumab-trbw), KRYSTEXXA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (pegloticase), UPLIZNA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (inebilizumab-cdon), and TAVNEOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (avacopan).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">GAAP earnings per share (EPS) increased 62% from $3.22 to $5.22, driven by mark-to-market gains on our BeiGene, Ltd. (BeiGene) equity investment and higher revenues, partially offset by higher operating expenses, including amortization expense from Horizon-acquired assets and incremental expenses from Horizon.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">GAAP operating income remained relatively unchanged at $2.0 billion, and GAAP operating margin decreased 5.8 percentage points to 25.1%.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Non-GAAP EPS increased 13% from $4.96 to $5.58, driven by higher revenues, partially offset by higher operating expenses, including incremental expenses from Horizon, and interest expense.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Non-GAAP operating income increased from $3.4 billion to $4.0 billion, and non-GAAP operating margin decreased 2.4 percentage points to 49.6%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The Company generated $3.3 billion of free cash flow in the third quarter of 2024 versus $2.5 billion in the third quarter of 2023, driven by business performance and timing of working capital items, partially offset by lower interest income.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 2</font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">References in this release to &#8220;non-GAAP&#8221; measures, measures presented &#8220;on a non-GAAP basis&#8221; and &#8220;free cash flow&#8221; (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. Refer to Non-GAAP Financial Measures below for further discussion.</font></div><div style="text-align:justify"><font><br></font></div><div id="i6a02bf03f592475888125c063f2dc750_7"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Sales Performance</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">General Medicine</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">Repatha</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (evolocumab)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales increased 40% year-over-year to $567 million in the third quarter, driven by 41% volume growth and 8% favorable changes to estimated sales deductions, partially offset by 10% lower net selling price. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">EVENITY</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (romosozumab-aqqg) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 30% year-over-year to $399 million in the third quarter, driven by volume growth.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">Prolia</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (denosumab)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales increased 6% year-over-year to $1.0 billion in the third quarter, driven by 9% volume growth, partially offset by lower inventory levels. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Oncology</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">BLINCYTO</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (blinatumomab)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales increased 49% year-over-year to $327 million in the third quarter, primarily driven by volume growth. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">Vectibix</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (panitumumab)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales increased 12% year-over-year to $282 million in the third quarter, primarily driven by volume growth. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">KYPROLIS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (carfilzomib)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales increased 8% year-over-year to $378 million in the third quarter, primarily driven by volume growth outside the U.S.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">LUMAKRAS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#47;LUMYKRAS&#8482; (sotorasib) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 88% year-over-year to $98 million in the third quarter, driven by volume growth and favorable changes to estimated sales deductions.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">XGEVA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (denosumab) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 4% year-over-year to $541 million in the third quarter, driven by higher net selling price.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:10.73pt">Nplate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> (romiplostim)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> sales increased 9% year-over-year to $456 million in the third quarter. U.S. government orders were $128 million in Q3&#8217;24 compared to $142 million in Q3&#8217;23. Excluding these U.S. government orders, Nplate sales grew 18% year-over-year in the third quarter, driven by 14% volume growth and higher net selling price.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">IMDELLTRA&#8482; (tarlatamab-dlle)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> generated $36 million of sales in the third quarter. Sales increased 200% quarter-over-quarter, driven by volume growth. IMDELLTRA is the first and only FDA-approved bispecific T-cell engager (BiTE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) therapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">MVASI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (bevacizumab-awwb) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales decreased 8% year-over-year to $195 million in the third quarter. Going forward, we expect continued sales erosion driven by competition.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 3</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Inflammation</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">TEZSPIRE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (tezepelumab-ekko)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales increased 67% year-over-year to $269 million in the third quarter, driven by volume growth.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">Otezla</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (apremilast) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales decreased 1% year-over-year to $564 million in the third quarter, primarily driven by 7% lower net selling price, partially offset by 5% volume growth.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">Enbrel</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (etanercept) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales decreased 20% year-over-year to $825 million in the third quarter, primarily driven by 13% unfavorable changes to estimated sales deductions and 12% lower net selling price. Going forward, we expect continued declining net selling price and relatively flat volumes.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">AMJEVITA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#47;AMGEVITA&#8482; (adalimumab) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 9% year-over-year to $166 million in the third quarter. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Rare Disease</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except for TAVNEOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the products listed below were added through the acquisition of Horizon on Oct. 6, 2023. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">TEPEZZA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(teprotumumab-trbw)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> generated $488 million of sales in the third quarter. TEPEZZA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">is the first and only FDA-approved treatment for thyroid eye disease (TED).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">KRYSTEXXA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(pegloticase)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> generated $310 million of sales in the third quarter. KRYSTEXXA is the first and only FDA-approved treatment for chronic refractory gout.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">UPLIZNA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(inebilizumab-cdon) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">generated $106 million of sales in the third quarter. UPLIZNA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">is used to treat adults with neuromyelitis optica spectrum disorder.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">TAVNEOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (avacopan) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">generated $80 million of sales in the third quarter. Sales increased 116% year-over-year, primarily driven by volume growth. TAVNEOS is a first-in-class treatment for severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis). </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:10.73pt">Ultra-Rare products</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, which consist of </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RAVICTI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (glycerol phenylbutyrate)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PROCYSBI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (cysteamine bitartrate)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACTIMMUNE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (interferon gamma-1b)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUINSAIR</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (levofloxacin)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BUPHENYL</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (sodium phenylbutyrate)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">generated $188 million of sales in the third quarter. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Established Products</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Our established products, which consist of </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EPOGEN</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (epoetin alfa)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Aranesp</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (darbepoetin alfa)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Parsabiv</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (etelcalcetide) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Neulasta</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (pegfilgrastim)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, generated $550 million of sales. Sales decreased 7% year-over-year for the third quarter, driven by volume declines. In the aggregate, we expect the year-over-year volume declines for this portfolio of products to continue.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6a02bf03f592475888125c063f2dc750_10"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 4</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Sales Detail by Product and Geographic Region</font></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Millions, except percentages</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;24</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;LUMYKRAS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMDELLTRA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enbrel</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMJEVITA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;AMGEVITA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEPEZZA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KRYSTEXXA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UPLIZNA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAVNEOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ultra-Rare products</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,979&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,172&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,151&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,548&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</font></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A &#61; not applicable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Change in excess of 100%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="33" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Horizon-acquired products, and the Ultra-Rare products consist of RAVICTI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, PROCYSBI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, ACTIMMUNE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, QUINSAIR</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and BUPHENYL</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Consists of (i) Aimovig</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RIABNI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, AVSOLA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, NEUPOGEN</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, IMLYGIC</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BEKEMV</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, Corlanor</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, WEZLANA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;WEZENLA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and Sensipar</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;Mimpara</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, where Biosimilars total $148 million in Q3 &#8217;24 and $104 million in Q3 &#8217;23&#59; and (ii) Horizon-acquired products including RAYOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and PENNSAID</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-bottom:1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:1pt;text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 5</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating Expense, Operating Margin and Tax Rate Analysis</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On a GAAP basis for the third quarter&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.4pt">Total Operating Expenses </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">increased 32% year-over-year. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Sales</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as a percentage of product sales increased 13.0 percentage points driven by higher amortization expense from Horizon acquisition-related assets and, to a lesser extent, higher royalties and profit share. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research &#38; Development (R&#38;D) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expenses increased 34% driven by higher spend in later-stage clinical programs, marketed product support, and research and early pipeline, including Horizon-acquired programs. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, General &#38; Administrative (SG&#38;A)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> expenses increased 20% primarily driven by commercial expenses related to Horizon-acquired products. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> operating expenses consisted primarily of an impairment charge associated with an IPR&#38;D asset and changes in the fair values of contingent consideration liabilities, both related to our Teneobio, Inc. acquisition from 2021.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.4pt">Operating Margin</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as a percentage of product sales decreased 5.8 percentage points year-over-year to 25.1%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Tax Rate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> decreased 2.4 percentage points year-over-year primarily due to the change in earnings mix as a result of the inclusion of the Horizon business, partially offset by quarter-to-date 2024 unrealized gains on our strategic equity investments, primarily BeiGene.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On a non-GAAP basis for the third quarter&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.4pt">Total Operating Expenses </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">increased 27% year-over-year. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Sales</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as a percentage of product sales increased 0.4 percentage points driven by higher royalties and profit share, partially offset by lower manufacturing costs and changes in sales mix. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">R&#38;D </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expenses increased 35% driven by higher spend in later-stage clinical programs, marketed product support, and research and early pipeline, including Horizon-acquired programs. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SG&#38;A</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> expenses increased 21%, primarily driven by commercial expenses related to Horizon-acquired products.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.4pt">Operating Margin</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as a percentage of product sales decreased 2.4 percentage points year-over-year to 49.6%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Tax Rate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> decreased 2.7 percentage points year-over-year primarily due to the change in earnings mix as a result of the inclusion of the Horizon business.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 6</font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Millions, except percentages</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;24</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;24</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Sales</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,310&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 pts.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research &#38; Development</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 pts.</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, General &#38; Administrative</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8) pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5) pts.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89%)</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Operating Expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,456</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,882</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,459</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,500</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27%</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Margin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">operating income as % of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8) pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4) pts.</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax Rate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.7</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.1</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.4) pts. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.4</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.1</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.7) pts.</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">pts&#58; percentage points</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A &#61; not applicable</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Flow and Balance Sheet</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The Company generated $3.3 billion of free cash flow in the third quarter of 2024 versus $2.5 billion in the third quarter of 2023, driven by business performance and timing of working capital items, partially offset by lower interest income. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">The Company&#8217;s third quarter 2024 dividend of $2.25 per share was declared on August&#160;2, 2024, and was paid on September&#160;6, 2024, to all stockholders of record as of August&#160;16, 2024, representing a 6% increase from this same period in 2023.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">During the third quarter, the Company reduced principal debt outstanding by $2.5&#160;billion. Year-to-date, the Company has reduced principal debt outstanding by $4.5&#160;billion. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Cash and investments totaled $9.0 billion and debt outstanding totaled $60.4 billion as of September 30, 2024.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.292%"><tr><td style="width:1.0%"></td><td style="width:54.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.690%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Billions, except shares</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;24</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Cash Flow</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital Expenditures</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free Cash Flow</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends Paid</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Repurchases</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Diluted Shares (millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note&#58; Numbers may not add due to rounding</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.292%"><tr><td style="width:1.0%"></td><td style="width:54.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Billions</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9&#47;30&#47;24</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12&#47;31&#47;23</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YTD &#916;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Investments</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt Outstanding</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note&#58; Numbers may not add due to rounding</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 7</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Guidance</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the full year 2024, the Company now expects&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Total revenues</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of $33.0&#160;billion to $33.8&#160;billion.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">On a </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP basis, EPS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of $8.71 to $9.56, and a </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">tax rate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of 9.0% to 10.5%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">On a </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">non-GAAP basis, EPS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of $19.20 to $20.00, and a </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">tax rate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of 14.0% to 15.0%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Capital expenditures</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to be approximately $1.3&#160;billion.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Share repurchases</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> not to exceed $500&#160;million.</font></div><div style="text-align:justify"><font><br></font></div><div id="i6a02bf03f592475888125c063f2dc750_13"></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third Quarter Product and Pipeline Update</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company provided the following updates on selected product and pipeline programs&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">General Medicine</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MariTide (maridebart cafraglutide, AMG 133)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">MariTide is a multispecific molecule that inhibits the gastric inhibitory polypeptide receptor (GIPR) and activates the glucagon like peptide 1 (GLP-1) receptor.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 2 study of MariTide is ongoing in adults who are living with overweight or obesity, with or without Type 2 diabetes mellitus. Topline data are anticipated in late 2024. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Planning for a broad Phase 3 program across multiple indications remains on track.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 2 study investigating MariTide was initiated for the treatment of Type 2 diabetes in patients with and without obesity.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMG 513</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Phase 1 study of AMG 513 was initiated and is enrolling patients living with obesity.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Olpasiran (AMG 890) </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Olpasiran is a potentially best-in-class small interfering ribonucleic acid (siRNA) molecule that reduces lipoprotein(a) (Lp(a)) synthesis in the liver. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">The Ocean(a)-Outcomes trial, a Phase 3 cardiovascular outcomes study, is ongoing in patients with atherosclerotic cardiovascular disease and elevated Lp(a). </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Repatha</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">EVOLVE-MI, a Phase 4 study of Repatha administered within 10 days of an acute myocardial infarction to reduce the risk of cardiovascular (CV) events, is ongoing. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">VESALIUS-CV, a Phase 3 CV outcomes study of Repatha, is ongoing in patients at high CV risk without prior myocardial infarction or stroke.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">In September data were presented from&#58; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.9pt">a sub-analysis of the FOURIER trial demonstrating that patients with obesity (BMI &#62;35) are at an increased risk of CV events. Repatha treatment of patients with obesity resulted in a reduction in the composite endpoint of CV death, myocardial infarction, stroke, hospitalization for unstable angina or coronary revascularization at 3 years &#91;HR 0.71 (0.59-0.86), and Absolute Risk Reduction &#61; 5.65%&#93;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.75pt">the SLICE-CEA study, the first randomized trial of Repatha in patients with asymptomatic severe high-risk carotid artery stenosis. The study demonstrated that 6 months of Repatha treatment led to significant reductions in lipid rich necrotic </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 8</font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">core (LRNC) volume (p&#61;0.017) and its components, intraplaque hemorrhage (IPH) (p&#61;0.037) and lipid volume (p&#61;0.023) in the carotid vessels, as assessed by MRI. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Oncology</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IMDELLTRA</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">IMDELLTRA is a first-in-class delta-like ligand 3 (DLL3) targeting BiTE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (bispecific T-cell engager) molecule.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">The Company is advancing a comprehensive global clinical development program across extensive-stage and limited-stage small cell lung cancer (SCLC)&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.9pt">DeLLphi-304, a Phase 3 study comparing IMDELLTRA with standard of care chemotherapy in second-line extensive-stage small cell lung cancer (ES-SCLC), is ongoing.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.9pt">DeLLphi-305, a Phase 3 study comparing IMDELLTRA and durvalumab with durvalumab alone, is enrolling patients with first-line ES-SCLC.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.9pt">DeLLphi-306, a Phase 3 study comparing IMDELLTRA with placebo following concurrent chemoradiation therapy, is enrolling patients with limited-stage SCLC. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.9pt">DeLLphi-308, a Phase 1b study evaluating subcutaneous tarlatamab, was initiated in patients with second line or later ES-SCLC.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.9pt">DeLLphi-303, a Phase 1b study of IMDELLTRA in combination with a programmed cell death protein ligand-1 (PD-L1) inhibitor +&#47;- carboplatin and etoposide, is ongoing in patients with first-line ES-SCLC.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.9pt">DeLLphi-302, a Phase 1b study of IMDELLTRA in combination with AMG 404 in patients with second-line or later SCLC, is complete. AMG 404 is an anti-programmed cell death protein 1 (PD1) monoclonal antibody.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">DeLLpro-300, a Phase 1b study of IMDELLTRA in patients with previously treated de novo or treatment-emergent neuroendocrine prostate cancer, is complete.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">In September, data were presented from&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.9pt">DeLLphi-301, a Phase 2 study of IMDELLTRA where extended follow-up data demonstrated sustained anti-cancer activity and a manageable safety profile in patients with ES-SCLC previously treated with platinum-based chemotherapy. Among 100 patients treated with the 10 mg dose level, the median duration of response was 9.7 months (95% CI, 6.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8210;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NE) and the median overall survival was 15.2 months. No new safety concerns were identified.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.75pt">DeLLphi-303, a Phase 1b study of IMDELLTRA combined with a PD-L1 inhibitor as first-line ES-SCLC maintenance therapy. With a median follow-up of 10.0 months (range 1.4 - 20.4), IMDELLTRA in combination with a PD-L1 inhibitor, demonstrated a manageable safety profile with durable disease control &#91;median duration of disease control&#58; 9.3 months (95% CI&#58; 5.6&#8211;not estimable)&#93; and notable survival outcomes &#91;median PFS 5.6 months (95% CI&#58; 3.6&#8211;9.0), 9-month Kaplan-Meier estimate for OS of 88.9%&#93;.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BLINCYTO</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Golden Gate, a Phase 3 study of BLINCYTO alternating with low-intensity chemotherapy, continues to enroll older adult patients with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell precursor acute lymphoblastic leukemia (B-ALL).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 1&#47;2 study of subcutaneous blinatumomab has completed enrollment in the dose-expansion and optimization phase in adult patients with relapsed or refractory Ph-</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 9</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">negative B-ALL. The Company is planning to advance blinatumomab subcutaneous administration to a potentially registration-enabling Phase 2 portion of this study with initiation in H2 2025. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Xaluritamig (AMG 509)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Xaluritamig is a first-in-class bispecific T-cell engager targeting six-transmembrane epithelial antigen of prostate 1 (STEAP1). </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The Company will initiate a Phase 3 study in post-taxane metastatic castrate resistant prostate cancer (mCRPC) in fourth quarter of 2024.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1 monotherapy dose-expansion study of xaluritamig is ongoing in patients with mCRPC and has completed enrollment of patients in a reduced monitoring after treatment administration cohort. A fully outpatient treatment cohort continues to enroll patients to further improve administration convenience.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 1 combination of xaluritamig with enzalutamide or abiraterone continues to enroll patients with mCRPC in dose-escalation and dose-expansion respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 1b study evaluating neoadjuvant xaluritamig therapy prior to radical prostatectomy was initiated in patients with newly diagnosed localized intermediate or high&#8208;risk prostate cancer.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 1b study was initiated and is now enrolling patients to evaluate xaluritamig in patients with high-risk nonmetastatic hormone-sensitive prostate cancer after definitive therapy.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">In September results were presented from&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.8pt">a Phase 1 dose exploration cohort evaluating xaluritamig monotherapy in patients with mCRPC where with a median follow-up of 27.9 months, the median OS was 17.7 months across all cohorts. An encouraging PSA90 rate (45.1%) was also observed in high-dose cohorts, and presence of PSA90 response was associated with survival (p &#61; 0.0044), potentially serving as an early indicator for benefit in these patients.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.75pt">a Phase 1 dose-expansion cohort evaluating xaluritamig monotherapy using multiple dosing regimens in patients with mCRPC demonstrated that the 1.5 mg Q2W target dosing regimen is the most favorable efficacy and safety profile and will be the recommended Phase 3 dose and schedule.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMG 193</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">AMG 193 is a first-in-class small molecule methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 1&#47;1b&#47;2 study of AMG 193 continues to enroll patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors in the dose-expansion portion of the study.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 1b study of AMG 193 alone or in combination with other therapies is enrolling patients with advanced MTAP-null thoracic malignancies.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 1b study of AMG 193 in combination with other therapies in advanced MTAP-null gastrointestinal, biliary tract, and pancreatic cancers is enrolling patients.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 1&#47;2 study of AMG 193 in combination with IDE397, an investigational methionine adenosyltransferase 2A (MAT2A) inhibitor, continues to enroll patients with advanced MTAP-null solid tumors.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 10</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 2 study evaluating the efficacy, safety, tolerability, and pharmacokinetics of AMG 193 was initiated in patients with MTAP-null previously treated advanced non-small cell lung cancer (NSCLC).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In September, data were presented from a Phase 1 dose-escalation and initial dose-expansion study of AMG 193 in patients with MTAP-null solid tumors. The data demonstrated monotherapy activity and an acceptable safety profile. These data open opportunities to explore both monotherapy and combination therapy development strategies.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Bemarituzumab</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Bemarituzumab is a first-in-class fibroblast growth factor receptor 2b (FGFR2b) targeting monoclonal antibody. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">FORTITUDE-101, a Phase 3 study of bemarituzumab plus chemotherapy, is ongoing in patients with first-line gastric cancer. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">FORTITUDE-102, a Phase 1b&#47;3 study of bemarituzumab plus chemotherapy and nivolumab in patients with first-line gastric cancer, has completed enrollment of the Phase 3 portion of the study.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">FORTITUDE-103, a Phase 1b&#47;2 study of bemarituzumab plus oral chemotherapy regimens with or without nivolumab, continues to enroll patients in first-line gastric cancer.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">FORTITUDE-301, a Phase 1b&#47;2 basket study of bemarituzumab monotherapy, is ongoing in patients with solid tumors with FGFR2b overexpression.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Nplate </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">The primary analysis of a Phase 3 study of Nplate as supportive care in chemotherapy-induced thrombocytopenia in gastrointestinal malignancies is complete. The Company continues to follow patients through a planned final analysis in H1 2025.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Data presentation at a medical congress is anticipated in mid-2025.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LUMAKRAS&#47;LUMYKRAS </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">CodeBreaK 202, a Phase 3 study of LUMAKRAS plus chemotherapy vs. pembrolizumab plus chemotherapy, is enrolling patients with first-line KRAS G12C&#8211;mutated and programmed PD-L1 negative advanced NSCLC.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Regulatory review by the European Medicines Agency (EMA) of the CodeBreaK 200 Phase 3 study of adults with previously treated locally advanced or metastatic KRAS G12C&#8211;mutated NSCLC along with data from the Phase 2 dose-comparison substudy is ongoing. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">The U.S Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) date for the Phase 3 CodeBreaK 300 study of LUMAKRAS plus Vectibix vs. investigator&#8217;s choice of therapy in KRAS G12C&#8211;mutated metastatic colorectal cancer (CRC) from October 17, 2024 to January 17, 2025 to allow time for review of recently submitted supplemental data.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">CodeBreaK 301, a Phase 3 study of LUMAKRAS in combination with Vectibix and FOLFIRI, is enrolling patients with first-line KRAS G12C&#8211;mutated CRC. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 11</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Inflammation</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TEZSPIRE</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">The Company is planning to initiate Phase 3 studies in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) and a BEC &#8805; 150 cells&#47;&#181;l or greater. Study initiation is anticipated in H1 2025. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 3 study of TEZSPIRE is ongoing in patients with chronic rhinosinusitis with nasal polyps. Data readout is anticipated in H2 2024. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 3 study of TEZSPIRE continues to enroll patients with eosinophilic esophagitis.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">In severe asthma, the WAYFINDER Phase 3b study and the PASSAGE Phase 4 real-world effectiveness study are fully enrolled.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The SUNRISE Phase 3 study continues to enroll patients.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Rocatinlimab (AMG 451&#47;KHK4083)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Rocatinlimab is a first-in-class T-cell rebalancing monoclonal antibody targeting the OX40 receptor.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">The eight study ROCKET Phase 3 program continues to enroll patients with moderate-to-severe atopic dermatitis (AD). To date, over 3,200 patients have been enrolled in the ROCKET program, with six studies having completed enrollment.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">In September, the Company reported results from the Phase 3 HORIZON study (part of the ROCKET program), evaluating rocatinlimab monotherapy vs. placebo in adults with moderate-to-severe AD. The study met its co-primary endpoints and all key secondary endpoints, achieving statistical significance versus placebo at week 24.&#8239;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.8pt">32.8% of patients in the rocatinlimab group achieved &#8805; 75% reduction from baseline in Eczema Area and Severity Index score (EASI-75), compared to 13.7% placebo treated (19.1% difference, p&#60;0.001). </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.75pt">19.3% of patients in the rocatinlimab group achieved a Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-ADTM) score of 0 (clear) or 1 (almost clear) with a &#8805; 2-point reduction from baseline, compared to 6.6% in placebo (12.8% difference, p&#60;0.001). </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.75pt">In the U.S., a more stringent scoring method was used (revised Investigator's Global Assessment, or rIGA) where 16.4% of patients in the rocatinlimab group achieved a score of 0 (clear) or 1 (almost clear) with a &#8805; 2-point reduction from baseline, compared to 4.9% in placebo (11.5% difference, p&#60;0.001). </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.75pt">Safety findings were consistent with those seen in the Phase 2b AD study.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Additional key data readouts from the ROCKET Phase 3 program are expected in late 2024 through H2 2025&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.8pt">ROCKET SHUTTLE is a 24-week study evaluating rocatinlimab in combination with topical corticosteroids and&#47;or topical calcineurin inhibitors in adult patients with moderate-to-severe AD. Data readout is anticipated in late 2024 to early 2025.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.75pt">ROCKET IGNITE is a 24-week study evaluating rocatinlimab monotherapy in adult patients with moderate-to-severe AD. Data readout is anticipated in late 2024 to early 2025.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.75pt">ROCKET ASCEND is a study evaluating rocatinlimab maintenance therapy in adult and adolescent patients with moderate-to-severe AD. Data readout is anticipated in H2 2025.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.75pt">ROCKET ASTRO is a 52-week study evaluating rocatinlimab in adolescent patients with moderate-to-severe AD. Data readout is anticipated in H2 2025.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 12</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 2 study of rocatinlimab is enrolling patients with moderate-to-severe asthma.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 3 study of rocatinlimab is enrolling patients with prurigo nodularis.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Otezla </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">In September data were presented from&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.8pt">a Phase 3 study of Japanese patients with Palmoplantar Pustulosis (PPP) demonstrating maintained or increased efficacy (compared with the week 16 primary analysis) and no new safety signals with 52 weeks of Otezla treatment. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.75pt">the DISCREET moderate-to-severe genital psoriasis study demonstrating that improvements in disease severity, symptoms, and quality of life with Otezla treatment were maintained at week 32.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No new safety signals were observed.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.75pt">the FOREMOST study of patients with oligoarticular psoriatic arthritis, where Otezla demonstrated sustained benefits in skin, joint, fatigue, and pain symptoms through 48-weeks. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Blinatumomab</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Blinatumomab is a bispecific T-cell engager (BiTE) molecule targeting CD19.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 2 study of blinatumomab was initiated in patients with autoimmune disease with an initial focus on systemic lupus erythematosus (SLE) with nephritis.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Inebilizumab</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Inebilizumab is a monoclonal antibody targeting CD19.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 2 study of inebilizumab was initiated in patients with autoimmune disease with an initial focus on SLE with nephritis.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Efavaleukin alfa (AMG 592)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Efavaleukin alfa is an interleukin 2 (IL 2) mutein Fc fusion protein.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 2b study of efavaleukin alfa in patients with ulcerative colitis was terminated due to the study meeting a prespecified futility threshold, and not related to safety concerns. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ordesekimab (AMG 714&#47;PRV-015)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Ordesekimab is a monoclonal antibody that binds interleukin-15.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 2b study of ordesekimab is ongoing in patients with nonresponsive celiac disease.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMG 104 (AZD8630)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">AMG 104 is an inhaled anti-thymic stromal lymphopoietin (TSLP) fragment antigen-binding (Fab).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 2 study was initiated in patients with asthma.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Rare Disease</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TAVNEOS </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 3, open-label study of TAVNEOS in combination with Rituximab or a cyclophosphamide-containing regimen is enrolling patients from 6 years to &#60; 18 years of age with active ANCA-associated vasculitis (Granulomatosis with Polyangiitis (GPA) &#47; Microscopic Polyangiitis (MPA)).</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 13</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TEPEZZA</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">In September, TEPEZZA was approved for the treatment of active Thyroid Eye Disease (TED) by Japan's Ministry of Health, Labour and Welfare (MHLW). Regulatory review in multiple additional geographies continues. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 3 study of TEPEZZA in Japan continues to enroll patients with chronic or low clinical activity score TED.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 3 study evaluating the subcutaneous route of administration of teprotumumab is enrolling patients with TED.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">KRYSTEXXA</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Data from the AGILE study evaluating the safety, tolerability, and efficacy of KRYSTEXXA administered with a shorter infusion duration in patients with uncontrolled gout receiving methotrexate as co-administration will be presented at the American College of Rheumatology Convergence (ACR) in November.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UPLIZNA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">The Company recently presented results of the Phase 3 MINT clinical study evaluating the efficacy and safety of UPLIZNA for the treatment of generalized myasthenia gravis (gMG).</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">UPLIZNA demonstrated a clinically meaningful and statistically significant Myasthenia Gravis Activities of Daily Living (MG-ADL) score improvement after two doses compared to placebo at Week 26&#58; -4.2 overall improvement, -1.9 placebo adjusted (p &#60; 0.0001, primary endpoint).</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.9pt">In the acetylcholine receptor autoantibody-positive (AChR+) population, UPLIZNA demonstrated a clinically meaningful and statistically significant MG-ADL score improvement compared to placebo at Week 26&#58; -4.2 overall improvement, -1.8 placebo adjusted (p &#61; 0.0015, secondary endpoint).</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">In the muscle-specific kinase autoantibody-positive (MuSK+) population, UPLIZNA demonstrated a clinically meaningful and statistically significant MG-ADL score improvement compared to placebo at Week 26&#58; -3.9 overall improvement, -2.2 placebo adjusted (p &#61; 0.0297, secondary endpoint).</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">UPLIZNA demonstrated a statistically significant Quantitative Myasthenia Gravis (QMG) score improvement after two doses compared to placebo at week 26&#58; -4.8 overall improvement, -2.5 placebo adjusted (p &#61; 0.0002, secondary endpoint).</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.9pt">In the AChR+ population, UPLIZNA demonstrated a clinically meaningful and statistically significant QMG score improvement compared to placebo at week 26&#58; -4.4 overall improvement, -2.5 placebo adjusted (p &#61; 0.0011, secondary endpoint).</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">In the MuSK+ population, the mean change from baseline in QMG score at Week 26 showed a trend favoring UPLIZNA but was not statistically significant (-5.2 for UPLIZNA and -3.0 for placebo, difference -2.3, p&#61;0.1326).</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.8pt">Patients who entered the study taking corticosteroids were tapered down starting at Week 4 to prednisone 5 mg per day by Week 24. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">The overall safety results during the placebo-controlled period of the study were consistent with the known safety profile of UPLIZNA.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">52-week data from the AChR+ cohort and from AChR+ and MuSK+ patients in the open-label period of the study will be presented at a future date.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Planning for regulatory submissions for gMG is underway. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 14</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">In August, the FDA granted Breakthrough Therapy Designation for UPLIZNA in the treatment of Immunoglobulin G4-related diseases (IgG4-RD) based upon data from the Phase 3 MITIGATE study. Regulatory filing activities for IgG4-RD are underway.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">MITIGATE results will be presented at ACR in November.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dazodalibep</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Dazodalibep is a fusion protein that inhibits CD40L. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Two Phase 3 studies of dazodalibep in Sj&#246;gren&#8217;s disease are enrolling patients. The first study is in patients with moderate-to-severe systemic disease activity, and the second study is in patients with moderate-to-severe symptomatic burden and low systemic disease activity.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Daxdilimab</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Daxdilimab is a fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 2 study of daxdilimab is ongoing in patients with moderate-to-severe active primary discoid lupus erythematosus refractory to standard of care.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 2 study of daxdilimab is ongoing in patients with dermatomyositis and antisynthetase inflammatory myositis.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fipaxalparant</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">Fipaxalparant is a lysophosphatidic acid receptor 1 (LPAR1) antagonist.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 2 study of fipaxalparant in patients with idiopathic pulmonary fibrosis is complete.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The study did not meet any of the primary or secondary endpoints.</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Development of fipaxalparant in this indication will be discontinued.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A Phase 2 study of fipaxalparant has completed enrollment of patients with diffuse cutaneous systemic sclerosis.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Biosimilars</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">In August, the FDA approved PAVBLU</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (aflibercept-ayyh) (ABP 938), a biosimilar candidate to EYLEA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (aflibercept), for the treatment of retinal conditions, including neovascular age-related macular degeneration (wet AMD), macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A randomized, double-blind pharmacokinetic similarity study of ABP&#8239;206 compared with OPDIVO</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (nivolumab) is enrolling patients with resected stage&#8239;III or stage&#8239;IV melanoma in the adjuvant setting.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A randomized, double-blind comparative clinical study of ABP&#8239;206 compared with OPDIVO is enrolling patients with treatment-na&#239;ve unresectable or metastatic melanoma. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.73pt">A randomized, double-blind combined pharmacokinetic&#47;comparative clinical study of ABP 234 compared to KEYTRUDA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (pembrolizumab) is enrolling patients with advanced or metastatic non-squamous non-small cell lung cancer.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">TEZSPIRE is being developed in collaboration with AstraZeneca.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">AMG 104 is being developed in collaboration with AstraZeneca.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Rocatinlimab, formerly AMG 451&#47;KHK4083, is being developed in collaboration with Kyowa Kirin.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi Company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 15</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Xaluritamig, formerly AMG 509, is being developed pursuant to a research collaboration with Xencor, Inc. </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">IDE397 is an investigational MAT2A inhibitor from IDEAYA Biosciences.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:107%">EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc. </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">OPDIVO is a registered trademark of Bristol-Myers Squibb Company.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">KEYTRUDA is a registered trademark of Merck &#38; Co., Inc.</font></div><div id="i6a02bf03f592475888125c063f2dc750_16"></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 16</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In this news release, management has presented its operating results for the third quarters of 2024 and 2023, in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. In addition, management has presented its full year 2024 EPS and tax guidance in accordance with GAAP and on a non-GAAP basis. These non-GAAP financial measures are computed by excluding certain items related to acquisitions, divestitures, restructuring and certain other items from the related GAAP financial measures. Management has presented Free Cash Flow (FCF), which is a non-GAAP financial measure, for the third quarters of 2024 and 2023. FCF is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company believes that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor&#8217;s overall understanding of the financial performance and prospects for the future of the Company&#8217;s normal and recurring business activities by facilitating comparisons of results of normal and recurring business operations among current, past and future periods. The Company believes that FCF provides a further measure of the Company&#8217;s liquidity.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company uses the non-GAAP financial measures set forth in the news release in connection with its own budgeting and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Amgen</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8217;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">s toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8217;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">s known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In 2024, Amgen was named one of the &#8220;World&#8217;s Most Innovative Companies&#8221; by Fast Company and one of &#8220;America&#8217;s Best Large Employers&#8221; by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and it is also part of the Nasdaq-100 Index</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, TikTok, YouTube and Threads.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon (including the prospective performance and outlook of Horizon's business, performance and opportunities and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 17</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain&#59; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 18</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">###</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONTACT&#58; Amgen, Thousand Oaks</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Elissa Snook, 609-251-1407 (media)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Justin Claeys, 805-313-9775 (investors)</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6a02bf03f592475888125c063f2dc750_19"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 19</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc. </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Statements of Income - GAAP</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In millions, except per-share data)</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,151&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,548&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,310&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,077&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,503&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,903&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,338&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,994&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,310&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,746&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,339&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,240&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,218&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,905&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,456&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,882&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,391&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,368&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,021&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,947&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,626&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(759)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,408)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,054)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,431&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,827&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,003&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,463&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,950&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.45&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.06&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in calculation of earnings per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6a02bf03f592475888125c063f2dc750_22"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 20</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Balance Sheets - GAAP</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In millions)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:64.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,011&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,944&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,317&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,268&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,362&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,518&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,602&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,766&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,332&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,156&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,941&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,920&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,641&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,658&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,629&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,383&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,611&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,883&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,154&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,768&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,949&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,544&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,312&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,392&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,854&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,170&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred tax liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,711&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,354&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term tax liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,280&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,680&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,527&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,232&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,883&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,154&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6a02bf03f592475888125c063f2dc750_25"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 21</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliations</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Dollars in millions)</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Three months ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Nine months ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP cost of sales</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,310&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,806&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,746&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,339&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to cost of sales&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,856)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(668)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,546)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,008)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to cost of sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,856)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(669)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,546)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,044)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP cost of sales</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,454&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,137&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,200&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,295&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP cost of sales as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP cost of sales as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18.0&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP research and development expenses</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,450&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,079&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,240&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,250&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to research and development expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (b)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to research and development expenses</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP research and development expenses</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,440&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,070&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,180&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,206&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP research and development expenses as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (b)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP research and development expenses as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP selling, general and administrative expenses</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,625&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,353&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,218&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,905&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to selling, general and administrative expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (c)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(47)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(255)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(138)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to selling, general and administrative expenses</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(255)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(151)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP selling, general and administrative expenses</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,565&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,293&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,963&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,754&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP selling, general and administrative expenses as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (c)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP selling, general and administrative expenses as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP operating expenses</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,456&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,882&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,391&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,368&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to cost of sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,856)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(669)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,546)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,044)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to research and development expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to selling, general and administrative expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(255)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(151)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives (d)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(183)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain other expenses (e)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(628)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(191)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(691)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,997)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,382)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,048)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,113)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP operating expenses</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,459&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,500&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,343&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,255&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 22</font></div></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.409%"></td><td style="width:0.1%"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Three months ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Nine months ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP operating income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,047&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,021&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,947&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,626&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to operating expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,997&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,382&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,048&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,113&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP operating income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,044&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,403&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,995&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,739&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP operating income as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to cost of sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to research and development expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to selling, general and administrative expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives (d)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain other expenses (e)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP operating income as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49.6&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47.2&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP interest expense, net</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(776)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(759)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,408)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,054)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to interest expense, net&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest expense on acquisition-related debt (f)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">788&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP interest expense, net</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(776)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(427)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,408)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,266)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP other income, net</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,830&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">685&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,288&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,431&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to other income, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income and other expenses on acquisition-related debt (f)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(313)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(607)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net gains from equity investments (g)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,608)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(170)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(693)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,305)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to other income, net</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,608)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(483)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(693)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,912)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP other income, net</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">595&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">519&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP income before income taxes</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,101&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,947&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,827&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,003&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to income before income taxes&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to operating expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,997&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,382&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,048&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,113&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to interest expense, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">788&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to other income, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,608)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(483)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(693)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,912)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to income before income taxes</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,231&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,355&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,989&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP income before income taxes</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,490&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,178&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,182&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,992&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP provision for income taxes</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">217&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">364&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,053&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to provision for income taxes&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments (h)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">228&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,007&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">442&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other income tax adjustments (i)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(33)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to provision for income taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">294&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">963&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">448&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP provision for income taxes</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">466&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">511&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,327&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,501&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP tax as a percentage of income before taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to provision for income taxes&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments (h)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other income tax adjustments (i)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to provision for income taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.7&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.7&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP tax as a percentage of income before taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13.4&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.7&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP net income</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,830&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,730&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,463&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,950&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to net income&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to income before income taxes, net of the income tax effect</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">960&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,348&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,547&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other income tax adjustments (i)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to net income</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">937&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,392&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,541&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP net income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,024&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,667&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,855&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,491&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Note&#58; Numbers may not add due to rounding</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6a02bf03f592475888125c063f2dc750_28"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 23</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In millions, except per-share data)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents the computations for GAAP and non-GAAP diluted earnings per share&#58;</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:54.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.386%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.386%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.386%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.390%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three months ended<br>September 30, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three months ended<br>September 30, 2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,830&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,024&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,730&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,667&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted EPS</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.22&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.58&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.22&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.96&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine months ended<br>September 30, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine months ended<br>September 30, 2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,463&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,855&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,950&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,491&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted EPS</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.40&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.52&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.06&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.92&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:3.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The adjustments related primarily to noncash amortization of intangible assets and fair value step-up of inventory acquired from business acquisitions.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three months ended September 30, 2024, the adjustments related primarily to noncash amortization of intangible assets from business acquisitions. For the nine months ended September 30, 2024, the adjustments related primarily to acquisition-related costs related to our Horizon acquisition. For the three and nine months ended September 30, 2023, the adjustments related primarily to noncash amortization of intangible assets from business acquisitions.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(c)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three and nine months ended September 30, 2024 and 2023, the adjustments related primarily to acquisition-related costs related to our Horizon acquisition.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(d)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three and nine months ended September 30, 2023, the adjustments related primarily to separation costs associated with our restructuring plan initiated in early 2023.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(e)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three and nine months ended September 30, 2024, the adjustments related primarily to impairment charges for in-process R&#38;D assets and changes in the fair values of contingent consideration liabilities, both related to our Teneobio, Inc. acquisition from 2021. For the three and nine months ended September 30, 2023, the adjustments related primarily to a net impairment charge for AMG 340.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(f)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three and nine months ended September 30, 2023, the adjustments included (i) interest expense and income on senior notes issued in March 2023 and (ii) debt issuance costs and other fees related to our bridge credit and term loan credit agreements, incurred prior to the closing of our acquisition of Horizon.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(g)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three and nine months ended September 30, 2024, the adjustments related primarily to our BeiGene equity fair value adjustment. For the three and nine months ended September 30, 2023, the adjustments related primarily to our Neumora Therapeutics, Inc. and BeiGene equity fair value adjustments, respectively.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(h)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The tax effect of the adjustments between our GAAP and non-GAAP results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Generally, the tax impact of adjustments, including the amortization of intangible assets and acquired inventory, gains and losses on our investments in equity securities and expenses related to restructuring and cost-savings initiatives, depends on whether the amounts are deductible in the respective tax jurisdictions and the applicable tax rate(s) in those jurisdictions. Due to these factors, the effective tax rate for the adjustments to our GAAP income before income taxes for the three and nine months ended September 30, 2024, was 58.6% and 18.8%, respectively, compared to 22.0% and 22.2% for the corresponding periods of the prior year.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(i)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The adjustments related to certain acquisition items, prior period and other items excluded from GAAP earnings.</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6a02bf03f592475888125c063f2dc750_31"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 24</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliations of Cash Flows </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In millions)</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"></td><td style="width:52.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.501%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.501%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.453%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,571&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,719&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,933&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,651)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,005)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,008)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,294&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in cash and cash equivalents</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,933)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,112&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,301&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,248&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,944&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,629&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,011&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,741&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,011&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,741&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,571&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,719&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,933&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(725)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(863)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free cash flow</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,994&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,070&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6a02bf03f592475888125c063f2dc750_34"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 25</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of GAAP EPS Guidance to Non-GAAP </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EPS Guidance for the Year Ending December 31, 2024</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:74.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP diluted EPS guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.71&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.56&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Known adjustments to arrive at non-GAAP*&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.38&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains from equity investments</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.01)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP diluted EPS guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.20&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.00&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">* The known adjustments are presented net of their related tax impact, which amount to approximately $2.39 per share.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(a) The adjustments primarily include noncash amortization of intangible assets and fair value step-up of inventory acquired in business acquisitions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, asset impairments, litigation, changes in fair value of our contingent consideration obligations and changes in fair value of our equity investments. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of GAAP Tax Rate Guidance to Non-GAAP</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tax Rate Guidance for the Year Ending December 31, 2024</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:74.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP tax rate guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rate of known adjustments discussed above</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP tax rate guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>amgn-20241030.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f792137b-fe40-436a-ac4b-fe11133d7e22,g:8da3bbc4-0fa2-4f60-a877-ef620ccf84e7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20241030" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amgen.com/20241030">
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20241030_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20241030_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20241030_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageDocument" roleURI="http://www.amgen.com/role/CoverPageDocument">
        <link:definition>0000001 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amgn_CoverPageAbstract" abstract="true" name="CoverPageAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_A2.00SeniorNotesDue2026Member" abstract="true" name="A2.00SeniorNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>amgn-20241030_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f792137b-fe40-436a-ac4b-fe11133d7e22,g:8da3bbc4-0fa2-4f60-a877-ef620ccf84e7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amgen.com/role/CoverPageDocument" xlink:type="simple" xlink:href="amgn-20241030.xsd#CoverPageDocument"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_25f85a0e-e3bb-4ca5-82bd-b43c9216f22c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntitiesTable_25f85a0e-e3bb-4ca5-82bd-b43c9216f22c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_d956d8f4-3834-4458-89f9-d3e5adebb3e1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_25f85a0e-e3bb-4ca5-82bd-b43c9216f22c" xlink:to="loc_dei_EntityListingsExchangeAxis_d956d8f4-3834-4458-89f9-d3e5adebb3e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_d956d8f4-3834-4458-89f9-d3e5adebb3e1_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_d956d8f4-3834-4458-89f9-d3e5adebb3e1" xlink:to="loc_dei_ExchangeDomain_d956d8f4-3834-4458-89f9-d3e5adebb3e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_10c8d2e1-6dce-45d9-9737-7c381d19cdb3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_d956d8f4-3834-4458-89f9-d3e5adebb3e1" xlink:to="loc_dei_ExchangeDomain_10c8d2e1-6dce-45d9-9737-7c381d19cdb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_cafa8ab6-4e0a-42ff-96f9-d2acf228c474" xlink:href="https://xbrl.sec.gov/exch/2024/exch-2024.xsd#exch_XNGS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_10c8d2e1-6dce-45d9-9737-7c381d19cdb3" xlink:to="loc_exch_XNGS_cafa8ab6-4e0a-42ff-96f9-d2acf228c474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_36c91bb2-5ae8-4b5f-9a07-8622c22c28b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_25f85a0e-e3bb-4ca5-82bd-b43c9216f22c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_36c91bb2-5ae8-4b5f-9a07-8622c22c28b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_36c91bb2-5ae8-4b5f-9a07-8622c22c28b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36c91bb2-5ae8-4b5f-9a07-8622c22c28b2" xlink:to="loc_us-gaap_ClassOfStockDomain_36c91bb2-5ae8-4b5f-9a07-8622c22c28b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_187a408d-0be6-40b6-bf3b-389dafaa772d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36c91bb2-5ae8-4b5f-9a07-8622c22c28b2" xlink:to="loc_us-gaap_ClassOfStockDomain_187a408d-0be6-40b6-bf3b-389dafaa772d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3603ed51-3408-4613-a598-2eb845a8a3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_187a408d-0be6-40b6-bf3b-389dafaa772d" xlink:to="loc_us-gaap_CommonStockMember_3603ed51-3408-4613-a598-2eb845a8a3a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_8b1e13bc-2982-4a20-aaba-b17568141601" xlink:href="amgn-20241030.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_187a408d-0be6-40b6-bf3b-389dafaa772d" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_8b1e13bc-2982-4a20-aaba-b17568141601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_85ceb047-1a29-458c-bef7-9f810a988ecd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityCentralIndexKey_85ceb047-1a29-458c-bef7-9f810a988ecd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_754bf88d-a30d-4766-a012-f059a75f2f89" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_AmendmentFlag_754bf88d-a30d-4766-a012-f059a75f2f89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4f8ae2f7-7fc0-40ac-bad7-13e26ad37b87" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_SecurityExchangeName_4f8ae2f7-7fc0-40ac-bad7-13e26ad37b87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_66ec2280-71ac-44dc-8217-afc359329cc7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_66ec2280-71ac-44dc-8217-afc359329cc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_9b67898d-16d7-4f4c-972d-9e2c8bc49407" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_PreCommencementTenderOffer_9b67898d-16d7-4f4c-972d-9e2c8bc49407" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_fb316144-d1c9-45cf-ab75-3b38958250dc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_SolicitingMaterial_fb316144-d1c9-45cf-ab75-3b38958250dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_4b32a3ed-4eca-4591-8fee-78992d076922" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_WrittenCommunications_4b32a3ed-4eca-4591-8fee-78992d076922" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_18582f79-c2c2-471a-adff-c1a101679f84" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_18582f79-c2c2-471a-adff-c1a101679f84" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1b9fbf72-0d56-4bba-bfcc-a0fe72ab3f31" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_DocumentType_1b9fbf72-0d56-4bba-bfcc-a0fe72ab3f31" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_db5b209d-73f4-4c52-b821-7e3091a33138" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_DocumentPeriodEndDate_db5b209d-73f4-4c52-b821-7e3091a33138" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_733c82c0-ccae-4e71-9f48-67cc919e0037" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityRegistrantName_733c82c0-ccae-4e71-9f48-67cc919e0037" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_00c24ad3-9abd-48c6-85a2-0ed3b7ff47ab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityFileNumber_00c24ad3-9abd-48c6-85a2-0ed3b7ff47ab" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_be9b1d87-ceea-409f-8e47-22f5faa2f528" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityTaxIdentificationNumber_be9b1d87-ceea-409f-8e47-22f5faa2f528" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ba6042b2-2ff6-44d9-bb35-48bedeee52bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityAddressAddressLine1_ba6042b2-2ff6-44d9-bb35-48bedeee52bc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_738fbd7c-140f-4564-b9f3-3c4ca0a1d54f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityAddressCityOrTown_738fbd7c-140f-4564-b9f3-3c4ca0a1d54f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_776f5f5f-5aca-4406-be45-d49c6d4e8d6c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityAddressStateOrProvince_776f5f5f-5aca-4406-be45-d49c6d4e8d6c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_acc345fc-7da8-4432-b4da-a7d8f518d30f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityAddressPostalZipCode_acc345fc-7da8-4432-b4da-a7d8f518d30f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a39bf6f6-3119-473d-b43e-5cb50ecb8874" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_CityAreaCode_a39bf6f6-3119-473d-b43e-5cb50ecb8874" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_787ef6f7-ed5b-45fd-a161-d4c1c33ddebe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_LocalPhoneNumber_787ef6f7-ed5b-45fd-a161-d4c1c33ddebe" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_67c1908b-8469-46f1-8da6-cbf3992d59a6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityEmergingGrowthCompany_67c1908b-8469-46f1-8da6-cbf3992d59a6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_55998ce4-38c1-4df4-87e0-dd6946d1df37" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_TradingSymbol_55998ce4-38c1-4df4-87e0-dd6946d1df37" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bdef42da-d1b3-43f1-b6ef-0f555f3d568a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_Security12bTitle_bdef42da-d1b3-43f1-b6ef-0f555f3d568a" xlink:type="arc" order="21"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>amgn-20241030_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f792137b-fe40-436a-ac4b-fe11133d7e22,g:8da3bbc4-0fa2-4f60-a877-ef620ccf84e7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ClassOfStockDomain_2de37ba1-a2d3-484d-9eec-bd8c8bcc93ae_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_242ea147-6128-4b3d-8636-885d9a408c78_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_d8ef70a8-b372-4e3a-9d52-6a7405ba85ae_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_746be11f-436c-4b6c-b797-3f7bff3e5762_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_668003ac-b879-4b82-9183-41b16e40b768_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_26b69947-4f8e-4f84-b9a3-78f30bd5510a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d1c43ec8-5872-4599-bcfd-282082a11fb8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_1a7bc939-4747-466a-b561-dd13ec9b4cd5_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6e3fa437-2e0b-47a1-8882-6dafa1929a6b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3900ace3-82a7-4254-91d8-49b067fe54ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4c870883-6e6d-4d98-80dd-948fcad18851_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e3f6b597-375d-42c8-81dc-22002fbc609b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1a7bcacd-88b9-4e0f-81db-ed0211b4ff82_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_94a56f5a-4762-4f33-9d79-7073359007a0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_5199456b-2f8a-4360-85df-d91d78b9f246_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_18ff1718-4883-4ebf-9c48-ecd7a1645783_terseLabel_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_label_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_documentation_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:href="amgn-20241030.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:to="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_35d3a2af-fdaa-4ed2-8690-618bcf7ca760_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CoverPageAbstract_64ba3aa3-1b61-4ad1-a372-eaa4dc279c14_terseLabel_en-US" xlink:label="lab_amgn_CoverPageAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover Page [Abstract]</link:label>
    <link:label id="lab_amgn_CoverPageAbstract_label_en-US" xlink:label="lab_amgn_CoverPageAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover Page [Abstract]</link:label>
    <link:label id="lab_amgn_CoverPageAbstract_documentation_en-US" xlink:label="lab_amgn_CoverPageAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cover Page [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CoverPageAbstract" xlink:href="amgn-20241030.xsd#amgn_CoverPageAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CoverPageAbstract" xlink:to="lab_amgn_CoverPageAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_590a2565-84c7-4ef5-8a50-278aefe5d7c0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8ed898b6-3993-46e8-9671-7e3d9c7c43dc_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f5e5c254-e4ce-4cd1-abc8-35266bfdca6a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_d6b1794c-7bad-43b4-8fa1-5f8386245f97_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_01462189-e5bf-4c71-a6ed-d0b3c5d3a589_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_53792595-0479-4a07-948b-6d3de7c622c1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_b02659bd-67f3-49d4-8b2b-74489bf66842_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_645588ed-a674-4be4-b16b-ed85d30b4b53_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_fb2346e6-db02-43c1-83c8-59a317dfc782_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_926f5203-cde9-4b08-a9f3-487193aa6591_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_49891f1f-f0f8-407c-af7f-4a6412d91e1f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_ea5920c5-061f-4863-8af7-4f9e62afc06a_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ac4604fb-2d28-4ae4-838f-bde5c126ec94_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNGS_6a6996ca-8437-4bb8-a989-570f0521057c_terseLabel_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]</link:label>
    <link:label id="lab_exch_XNGS_label_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS" xlink:href="https://xbrl.sec.gov/exch/2024/exch-2024.xsd#exch_XNGS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNGS" xlink:to="lab_exch_XNGS" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>amgn-20241030_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:f792137b-fe40-436a-ac4b-fe11133d7e22,g:8da3bbc4-0fa2-4f60-a877-ef620ccf84e7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com/role/CoverPageDocument" xlink:type="simple" xlink:href="amgn-20241030.xsd#CoverPageDocument"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CoverPageAbstract_1325f24a-699f-4a46-896e-65146ff0d4c1" xlink:href="amgn-20241030.xsd#amgn_CoverPageAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_25f85a0e-e3bb-4ca5-82bd-b43c9216f22c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_CoverPageAbstract_1325f24a-699f-4a46-896e-65146ff0d4c1" xlink:to="loc_dei_EntitiesTable_25f85a0e-e3bb-4ca5-82bd-b43c9216f22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_d956d8f4-3834-4458-89f9-d3e5adebb3e1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_25f85a0e-e3bb-4ca5-82bd-b43c9216f22c" xlink:to="loc_dei_EntityListingsExchangeAxis_d956d8f4-3834-4458-89f9-d3e5adebb3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_10c8d2e1-6dce-45d9-9737-7c381d19cdb3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_d956d8f4-3834-4458-89f9-d3e5adebb3e1" xlink:to="loc_dei_ExchangeDomain_10c8d2e1-6dce-45d9-9737-7c381d19cdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_cafa8ab6-4e0a-42ff-96f9-d2acf228c474" xlink:href="https://xbrl.sec.gov/exch/2024/exch-2024.xsd#exch_XNGS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_10c8d2e1-6dce-45d9-9737-7c381d19cdb3" xlink:to="loc_exch_XNGS_cafa8ab6-4e0a-42ff-96f9-d2acf228c474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_36c91bb2-5ae8-4b5f-9a07-8622c22c28b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_25f85a0e-e3bb-4ca5-82bd-b43c9216f22c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_36c91bb2-5ae8-4b5f-9a07-8622c22c28b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_187a408d-0be6-40b6-bf3b-389dafaa772d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36c91bb2-5ae8-4b5f-9a07-8622c22c28b2" xlink:to="loc_us-gaap_ClassOfStockDomain_187a408d-0be6-40b6-bf3b-389dafaa772d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3603ed51-3408-4613-a598-2eb845a8a3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_187a408d-0be6-40b6-bf3b-389dafaa772d" xlink:to="loc_us-gaap_CommonStockMember_3603ed51-3408-4613-a598-2eb845a8a3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_8b1e13bc-2982-4a20-aaba-b17568141601" xlink:href="amgn-20241030.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_187a408d-0be6-40b6-bf3b-389dafaa772d" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_8b1e13bc-2982-4a20-aaba-b17568141601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_25f85a0e-e3bb-4ca5-82bd-b43c9216f22c" xlink:to="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_85ceb047-1a29-458c-bef7-9f810a988ecd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityCentralIndexKey_85ceb047-1a29-458c-bef7-9f810a988ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_754bf88d-a30d-4766-a012-f059a75f2f89" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_AmendmentFlag_754bf88d-a30d-4766-a012-f059a75f2f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4f8ae2f7-7fc0-40ac-bad7-13e26ad37b87" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_SecurityExchangeName_4f8ae2f7-7fc0-40ac-bad7-13e26ad37b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_66ec2280-71ac-44dc-8217-afc359329cc7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_66ec2280-71ac-44dc-8217-afc359329cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_9b67898d-16d7-4f4c-972d-9e2c8bc49407" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_PreCommencementTenderOffer_9b67898d-16d7-4f4c-972d-9e2c8bc49407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_fb316144-d1c9-45cf-ab75-3b38958250dc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_SolicitingMaterial_fb316144-d1c9-45cf-ab75-3b38958250dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_4b32a3ed-4eca-4591-8fee-78992d076922" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_WrittenCommunications_4b32a3ed-4eca-4591-8fee-78992d076922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_18582f79-c2c2-471a-adff-c1a101679f84" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_18582f79-c2c2-471a-adff-c1a101679f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1b9fbf72-0d56-4bba-bfcc-a0fe72ab3f31" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_DocumentType_1b9fbf72-0d56-4bba-bfcc-a0fe72ab3f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_db5b209d-73f4-4c52-b821-7e3091a33138" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_DocumentPeriodEndDate_db5b209d-73f4-4c52-b821-7e3091a33138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_733c82c0-ccae-4e71-9f48-67cc919e0037" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityRegistrantName_733c82c0-ccae-4e71-9f48-67cc919e0037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_00c24ad3-9abd-48c6-85a2-0ed3b7ff47ab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityFileNumber_00c24ad3-9abd-48c6-85a2-0ed3b7ff47ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_be9b1d87-ceea-409f-8e47-22f5faa2f528" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityTaxIdentificationNumber_be9b1d87-ceea-409f-8e47-22f5faa2f528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ba6042b2-2ff6-44d9-bb35-48bedeee52bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityAddressAddressLine1_ba6042b2-2ff6-44d9-bb35-48bedeee52bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_738fbd7c-140f-4564-b9f3-3c4ca0a1d54f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityAddressCityOrTown_738fbd7c-140f-4564-b9f3-3c4ca0a1d54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_776f5f5f-5aca-4406-be45-d49c6d4e8d6c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityAddressStateOrProvince_776f5f5f-5aca-4406-be45-d49c6d4e8d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_acc345fc-7da8-4432-b4da-a7d8f518d30f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityAddressPostalZipCode_acc345fc-7da8-4432-b4da-a7d8f518d30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a39bf6f6-3119-473d-b43e-5cb50ecb8874" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_CityAreaCode_a39bf6f6-3119-473d-b43e-5cb50ecb8874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_787ef6f7-ed5b-45fd-a161-d4c1c33ddebe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_LocalPhoneNumber_787ef6f7-ed5b-45fd-a161-d4c1c33ddebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_67c1908b-8469-46f1-8da6-cbf3992d59a6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_EntityEmergingGrowthCompany_67c1908b-8469-46f1-8da6-cbf3992d59a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_55998ce4-38c1-4df4-87e0-dd6946d1df37" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_TradingSymbol_55998ce4-38c1-4df4-87e0-dd6946d1df37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bdef42da-d1b3-43f1-b6ef-0f555f3d568a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_df3d4654-6c83-4cf3-baf3-67ce82fc1fe3" xlink:to="loc_dei_Security12bTitle_bdef42da-d1b3-43f1-b6ef-0f555f3d568a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>amgenlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 amgenlogo.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ") ;H# 2(  A$! Q$!_\0
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M-<?\)!"V[_EDUE"4'T&VOG^BOJ(Y+EL598>'_@*/G)9MF$G=UY?>SZC\-_\
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M]P**** "BBB@ K!\=>--,^'OA+4_$.KSI;V-C"TKLQQN/\*C@\L< <=ZWJ^
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M3VK#J5*,FXIZK<IQDDI-:,[/X/\ Q(OOA/\ $/1_$MB[!K28>;&"0)8CPZ$
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ME\9_^AVF_P# &U_^-5]5]3XG_P"@J'W+_P"0/F_K7#O_ $#3^_\ ^W/>(_\
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M10 44NT^E&T^E "5^J_[,/\ R:#H/_8-OO\ T=/7Y4[3Z5^JW[,/_)H6@_\
M8-OO_1T]? <9_P"Y4O\ KXORD?;\)_[W5_P/\T?E5)_K&^IIM.D_UC?4TVOT
M![GPZV% +$ #)/:@@J2",$5<T7_D,6/_ %W3_P!"%?7_ .W=^S7#X7N/^%B>
M&;&*VTFY<#5[>)@JQ3NP"RJGHY."!T;!QR<>7B,PI87%4<-4T=2]GYJVGSOI
M]QZ5# U<1AZN(IZJG:Z\G?7Y6U/C.BBBO3/."BBB@#]*_P#@G3_R1'4/^PM)
M_P"BXZ^J*^5_^"=/_)$=0_["TG_HN.OJBOYRX@_Y&F(_Q,_?,C_Y%M#_  H*
M***^?/<"BBB@ JOJ&H6VDV%S?7D\=K9VT3333RL%2-%!+,Q/0  DGVJQ7@7[
M;OQ$?P#\!M5AMI6BOM;D73(BCJ&5'!:4X/52BLAQT\P5VX+#2QF)IX>.\FD<
MF+Q$<)AYUY;139^:_P 6_'MS\3OB1XA\3W6X-J-V\D:,P8QQ#Y8TR ,[4"KG
MVKD:**_IRG3C1A&G!625EZ(_G:I4E5FZDW=MW?S"BOH7]E3]EN+]H1==NM1U
M.YTC3M/V1I/;(CEY6R=I#>PSFOH'_AV?X:_Z'35?_ 6*OG\9Q%EV!K2P]>=I
M+?1OSZ'N87(L?C**KT87B]M4C\^:*_0;_AV?X:_Z'35?_ 6*C_AV?X:_Z'35
M?_ 6*N/_ %MRG_GX_P#P%_Y'7_JQFG_/M?\ @2_S/SYHKTG]H3X5VGP9^)VH
M>%[*_FU*WMHXW%Q<($8[E!(P..]>;5]50K0Q%*-:F[QDKKT9\U6I3H5)4JBU
MB[/Y"K]X?6OTS^,'_)AME_V+FF?^BX:_,Q?O#ZU^F?Q@_P"3#;+_ +%S3/\
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MN*JU*=/1R;7O+9OU/V3!Y]E=+#4J<ZFJBD]'NEZ'VI_PCND_] NS_P# =/\
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M ,M@HHHKZ \,_2O_ ()T_P#)$=0_["TG_HN.OJBOE?\ X)T_\D1U#_L+2?\
MHN.OJBOYRX@_Y&F(_P 3/WS(_P#D6T/\*"BBBOGSW HHHH *_.?_ (*.>/CK
M7Q*TCPM$Y,&B6GF2*T8!$TV&.&[C8(OH<U^BEQ<16=O+//(L,$2EY))" JJ!
MDDD] !7XP?&#QDWQ!^)WB7Q"P*+?WTLR(9?,"(6.U0W< 8 ^E?H7!>$]MC98
MAK2"_%Z?E<^%XNQ7LL'&@MYO\%K^=CCZ**OZ!I<FN:Y8:?%D274Z0J0I;EF
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M\T1KTW.BNQ_%F)_&O):]F_;%_P"3D_&__7S'_P"B8Z\9K]ERUN6!H-_R1_\
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9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46205619795008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>Oct. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 30,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amgen Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320-1799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNGS', window );">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNGS', window );">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member] | 2.00% Senior Notes Due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.000% Senior Notes due 2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNGS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNGS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M]:T(<"]8+Q8T4_M";9G+>Q68NXK+)U[I__J3W;1^0W"=#-?!U ^X0^@[R0+
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M$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( ,& 7EF7BKL<P
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M/UY_ 5!+ 0(4 Q0    ( ,& 7ED'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ P8!>67QWC8WM
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ P8!>69E<G",0!@  G"<  !,              ( !RP$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " #!@%Y9OLW]!/D$  ![%0  &
M            @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ P8!>69^@&_"Q @  X@P   T              ( !.PT  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " #!@%Y9EXJ[',     3 @  "P
M    @ $7$   7W)E;',O+G)E;'-02P$"% ,4    " #!@%Y9VU\'[3D!   P
M @  #P              @ $ $0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ P8!>620>FZ*M    ^ $  !H              ( !9A(  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ P8!>6660>9(9 0  SP,
M !,              ( !2Q,  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  E10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>3</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="amgn-20241030.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="amgn-20241030.htm">amgn-20241030.htm</File>
    <File>amgn-20241030.xsd</File>
    <File>amgn-20241030_def.xml</File>
    <File>amgn-20241030_lab.xml</File>
    <File>amgn-20241030_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "amgn-20241030.htm": {
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20241030",
   "dts": {
    "inline": {
     "local": [
      "amgn-20241030.htm"
     ]
    },
    "schema": {
     "local": [
      "amgn-20241030.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "amgn-20241030_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20241030_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20241030_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 2,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 1,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 3,
   "elementCount": 32,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 27
   },
   "report": {
    "R1": {
     "role": "http://www.amgen.com/role/CoverPageDocument",
     "longName": "0000001 - Document - Cover Page Document",
     "shortName": "Cover Page Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:PreCommencementIssuerTenderOffer",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amgn-20241030.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:PreCommencementIssuerTenderOffer",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amgn-20241030.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "amgn_A2.00SeniorNotesDue2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.amgen.com/20241030",
     "localname": "A2.00SeniorNotesDue2026Member",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.00% Senior Notes Due 2026 [Member]",
        "label": "2.00% Senior Notes Due 2026 [Member]",
        "documentation": "2.00% Senior Notes Due 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "amgn_CoverPageAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.amgen.com/20241030",
     "localname": "CoverPageAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover Page [Abstract]",
        "label": "Cover Page [Abstract]",
        "documentation": "Cover Page [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Listings, Exchange [Axis]",
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange [Domain]",
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "exch_XNGS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/exch/2024",
     "localname": "XNGS",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]",
        "label": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0000318154-24-000042-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000318154-24-000042-xbrl.zip
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M'0M" EKT'6P9/X^W^]2S3/@G->_P6.!]GN4QW$*!W%NP3 KG8T0!<1UBPN_
M1O$F"\[SCH;P3UP;O@0W8OAN$/#7&JX?7V$1\%U"P1H("AP0V@EL'#AWSQT
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M,%CL&S#)CUI)3VQ.4/(6-$J?^HR85H!V:J*+I+7$ *Q9'ZS:H>4'"/^B8=,
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MI]MI=LL+)-3M9-W7R/_T]?/ILX&\L0!ZZ]%LLZ5M:3ILJ\>&0(- S(%@!5:
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M&["#$&#DZ+QW>7I,[@#E)_ OCW/O<JFL-42@#V.$7"8YTGYP@+X]F_X= 7,
M>O?],4+AJ'O]VW'J\8I\7%#PTMOURG$B\"1?N6-!P&SX @6%%_X,4-0.IN2B
MUWW 4MGS0/^5@Q\:37._T.[%6>?\O-]K*VMB@]9$#&3AX^0B?.;8-)D=TB*/
ML -,D;@JY.CL_!Q(*:3^B''%]KW5[VQB6_52M;'6QI8$+S;3*%9*U>9RB\H!
MJ-/X!CP0K5'=W7F\^94<#6:I$OVBP6P;%/ 1L#9_YB=6IO2&?;UQDABBOWE'
M'0-1FG+YX[,Q<P) *#*RW0%HL@:\%W$)Z.*.V:['-<J%R#8 7#Q4! MHQ*1$
MFH!U9<I?1+2 '[<=P<<,+(KSR='-Z?GI\1-*QY3=_@R[_8R=GWMCJU@I5],^
M,F%,X*%3'K^9L45NIO#.,F "2T\G:!"HAZ ?GWH8.@?3Q7 =L\C34!8Q8-5Y
M=VZ*_,CG'*3JZ+=P]+7UCAY)UXS\.PJ:)!T(3$C]F]J@H!96!)_YS4*:<J20
MAZW.=QOG6W\":8-=8;"!F\H+!DHV(M]'WL[)W*>F)?Q4DN ?//-Y7L_/7/EA
MMW'HS=FA:P-YZ@QI5;A?@VA@1,#&F1L%J+R"JDB!B@L+Z21+'BK!V0DG8M?G
MN82^HN9M'FPEXV!!#J<L%P?)>V Y@DJ%8S'6RR9PJ%SV<F<VD5D6TIPI:N3H
M^JQXKAW/$I')_^.MC(LHZ >NAR:%(X+Q8%: J6&RA\/[BNGO!DWTYZ )YE%5
MR]559%^<)WL\3'[X*$UL%K+2[ 4!CYL[H55\&/$XQFEHX#FN 1H$6!/XU, U
M,[+3\F7KY:],[0F5QAQ1?!<0I;P&HLPC UB"=Q;(#7LJ(@EPLB8CCGOG(FXD
MP84BFS!_A'J#PR+?98[I&KXL( )U(&12]9]'H9P?^EX;^.E8>>'A8+GBT5O@
MT=J,]/0LRKL?X^EP ]KDZ>:HDQ<C3QS=7*PO ,A3^+PIF*XTJGF-$(:\19W\
MA#J@A8N)-W3(0EX+.+1XW<$"C4M9G47KL9T BD T*0YX0#[M   I  L;$:U<
MGKUT[F$,.FAE,AD1TX6]V^@^$C%3D!(6" XP*X54 G  ;GJP3Y%[WRHUXGCF
M4:OVEIQV"Z1>:CWQA-L8B/U^MJZ5=^DOO>R(^$X*;%@ZA,Z5 *QR"W1]#C*M
M5M(ES$KDT@5F?!^?/IIVS'<"P04L)%=K:#%S=QK::T@8>((J+Q2TF&S@7E3.
M4[HY'.^R?DVP; A8!K( DM#D'^(-$E-FK 3[191+Y82J1!<)K50E1:*72]7C
MPJ.FQ<*J"O.<Z2&V$_N0^+4XTQ>P,O1=6^2^9#"$A?M$;E>K5%E@#.+W&G;.
M!5+53K 6'DMZ)OBQ8YX7P^D'?A=+BXDFR0Y,+^#ZPPV^*_,;E>0;K5(9X-4J
M\KO()XS2.L4+9@$K%I\.&<\'NKK!C32;I99(T-GO0HSWY]W+TZ_]*Z6Z;4YU
M^^C: !GR$3!HV9L'N!2? :$VF&:.</((#QS0.><'//<M+:@+G(0L[!G'NT1P
M%Q[!#_FB0'5!)P#) 6H D,/(<5'H7X\MFYK,!F9&X<6@.KJ!BTD&U^/CHL-&
M//I(WHM0'B@21N0'R+1X-K4]G7AC=V#3 %.*;!;=L@F\YNA]L7U^?JS,@"W4
M.LHA53,DFG,*#FQD\]'$1><^W)^8:*;$%![NDRDDJ,<5V3</ELHS&(&ONAXP
MO#BET>,?C N?%_ * ]4>(A0@A\^&/FBM6 !_/2[N+M-,I9.]VG2R5M:!/Y$#
M[0;L*9X+3%3DA:8"^EY<D0[,7@3WV3R5S]%_7!8C%2]\9J[FSV>CY&H1M,T!
MC_[$UJSG^K&^!ON**RTXN<OH@LRX_DU'C*CM>3'7G]2.?"N$-X]$-6JMW%)]
M5C8HP]( STK56IE+E,K4"JQO14!@)YBPR0#^RPCS $&9;4DO](AQ!$[\E1HY
MNNEWVM=:5NUAO@YWKYW3:;YU;_%:8A&07-)\T6\%AU,,Z3<\OPD+*1X5+R,5
M!BCZCRQ,6 D7_<[D:'+:NS[E:;!#-_*!-?TM6WW!H?,&*>J0-W?(LY8&&/N)
MDX<6%,E$-?TV3^\KPXW\2+G^N5)E3=<%S2J X!Y8!_HO>,8;*G&I.HD%86BX
M8Y!O)=+F+="GZ#*0KTP](V[*M+%F;E$7WN#CYHDUP<9L;/E3SAUSX&Y#Q4:V
M8A3->;@6,(^C&'/^@9_P!Y,'0^G 0D;CNPY[^+!3" IX)S ],*@MJ[XPO6H>
M^]'US="%S^S<1T,/X_ S,F5 &Z;F?Z,[E"!I7(@YEB@!QC)P:O)LV%C,@!4[
MF3Z63[/H4[%= TL'^:V 4]S[&'(TPSHP!%^Y><*KP1:DF<*/;>)'9M,=/O)B
M.0\..8% )S8OQA9Q85;IY[A.2I4!,0*BB<&.T(>']MVB)B/$E<F&?$UW,[>_
M0HHM59Z+FN(@A_%TT&PQ_G#)[O]50$TK\*C!]CZ85A9]L9+PF8@D@^B$I:1U
MM#0G3Q-?6N=<H42*Z/O]ZKB9WBBU9$!H+GI]=2,"KXU9L%I60_#,=[ZN )1'
M![B% <=#1]QS<M-NE7DO>7)4K96TM\?\+=0.7.(. &9W0GYP+L%W*]\D:L$%
MSAF\ ;Q\53IP#C:Q:UBS$'P2[3KR9+DX-M2O8K@O[>3!SW)]F.=S,>K;T[A'
M(8@D#&4-F -L)W8$P]=B4*H@\B:#R/.(G](9UT?[*,"K2>M)> ]OU<5& #XG
MHV^AH(KE"G.>S5&J83K'[_H?TK^R\#H4CYQ"0&Z1(;US1<B7#;'HW!#Y*0NQ
M8=$F$0AF(%OK,%#,)R(3)G8"<#+@SQIC,.*RZL/VR8O(&S2W=M=(\14(;0GB
M3)^AJ$Q*6M*!!C:>VK .T/]YIP6P[XXN^NWCHN&Z'O-IK(KQ1%;>Q-YRDL?0
MKSB$FP!!:^3HNG?1KZ6RJI5BMK7XIC98#'/&./"XL2ZC)&8F+GC8Z068[=3&
MCR%F7!\7'1R))\9I8E3%#U9$2.?B([)[AT**;9IP*43@I6MH8V?E-W%Y*0TJ
M"_OYKBYV2M %<4&@0@@(0@UL_LX/"PMJV;JJD3KHES[HM<[7R3I'WJ ?>T%A
M'I>#S2\'EFUA_R;LS1U*'9SR#E4B_("&^0IL4>>_B^R6AY"@>]:IM!H%T64L
MZ?S-RU&0]<-?R/$%[Y\7[GH;6'^[K[>/TQF03Q M,QQ+BXW5**)27W*BPQ]@
MZHM6?H'<%\6?UN)/,6=*6>JH"<8F<4':PP7@(#:P&A0W^"\N9\;4GU##O84O
M@K )TMSMD7C#C-MD5'8D/ GG0*[JTW#)NS3D783M=6A\O3HMLN@#FH\E"B2P
M5T;44^)P%8K,"22>3;9<>)3V*,V7&V'?9!PZE)'XSU\6R->!+0UVD(<6481K
MED*3NW(9 <$UGO\(O#LMOY/,@503&K&X4::JG4]ALB*SGN$PKS#Z!SMLY)SB
M]IHISP$ZTSDTM :^2%<G(]^]Q\IVGJ<\F\VE#\C1AX\?>OH@W0XLJ[ Y[\EC
M>WV4'T#QZO8_GW6*6KK ,E4K,9@[;,^.@H6RB#7[&<1#VV0 7IWJEDYUKK4!
MM_+6/UQ1\F7Q=IA(Z6L?;^'!A#+4W)+97@^Y]G9PH@HOMX27E26\U!_$2Q<'
MC,XA9Q)\6YSVEV#L(ZX%3&5=R: 4'FP##^;*^A,\&-#@EH6KT"&EWSXL?>8B
M"_P7H7'PTF]0F<% "#('.^^3UGOI\1&5"ETWV^K3\ZT).K#34QLRM"5Y&B#\
M@H@;:1CUY%T?T9&:XEX(;9Y''6(IZ, UIB&:=A;O<[_H/Y^+A\SW$$IG_\\Q
M.Y%\DTJL@^]$(][<"BN;T"RVA)XM-X3E19HH+\J#_-V!@^,,#6SI-DB&2XAL
M)DQ5!?".D&6(?DUS4V(GEEF<@]Q>LI+SSQ?M3[WV#>?"\(^O^ _%63;(64Y=
MD[WW&?V$=)=I?L5GDJ&<WP4EXF$Q%HBYAZRS-3J,\B]\U/13V9IA$H5)KFZJ
M)9GH79$43B8>T,LG=*I3B/(<1.FQ46137NF-GFAVCZ,&T&#J1#[(#>J0"^12
M\+* M$?,,:;DJ'/1/H[MJC2BE9>Q+)ZPO:)A&<^SAW\G!XYCO&8IUZNPAZ,%
MSQ>0Q2#<@\F]L3,34!<^5]EC-4"G:S20]6IJ]MO6])O/I1ORP74%R9_YT8BT
MYTNKCCZ< 3HE[;7X 8(T-'S+X]?Y,Y]A6>0#8Z1MA-BK\/,'>,:,&[FD[?X9
M0E8 (5>PNR]8SS.POG%6-PLUNSY'M,8),CO7$FF\J?SD5?B8+GA$<,/;4:S+
M4,UI[_18(.>5$;J8IJXU"B(*">K4?Z@3H?XG?ZOQ$F^N885@A/+M2<+D7;@,
M.#/,"(X&$RL4+<<\T-C0 X)1!J #Q2ZW(E<K*]R:":)E)3@D>(?$\.'J_$.W
MU_U>40KH]0 74WD*.=&,#S%/07LD3R$']H=6PZ$]SM &19,38HY0(MM8ZG?^
MNKGN]CJ*C6]MQDJZ)4O2Y"#-V65&XD(E!L@"7B@$3]WQ48!B5"#VX') %7!!
MV_0C0^2G1_9$#)J,^^8=G5Y=GQW+EJ#O.Z<$0-4LUTZ(5BOS?(^ 6\L__: U
MM1,;%>,15YK]$KF131=F#5R6_ :QPT6IMUO((4I)_YAX'W0?QPCBCRV>Q!ZA
MC(TKD6F Q<NN/?5 ->6.(SAV$Z,/&:>LBP89ZI1W=,J/)Y@R/&#7&ULV'#@+
MX"\ZPM-66OIF:X(E+P:S;#RAHB[TC_97T*;.0+.2!QJGIL?]>Z_;-S?MCYUD
M1CT0GEV\=WW;Q'Q T0+"03^M? S>+QJ/B)-/=>Q]9?YM%*<WGR][W9O. K$\
M1"#[[=/NN0:FB]K8R58T&ZO61++[I]\^5<O-RO%6D"%[<4H@;-)EFC[YK"0U
MV>K,9P-JR]E]&?EGJ>PT9#Y7?U;+21:;D@X;5O[Y39)']:Y./W7ZL\0A.3IQ
MC29"T@ HAFXQEC>AZX&@A]_1VD2M[JA]=EPB?9=[*PL\0X!4"GJZ*_^8@H4P
M8,Q)!$E<KBB7)I=4D-D'UK?$*(%'Q72PY80HA4-;F^$1ILQ)GV%T'DXB[D6R
M$):HD-^N>MV_KBXE]AUYU$^2U^;/^[B0+DOPTVPGG8K-PW5R8%S<VW<UAK;/
MTI/J)RR4DZV+<2("<TP/4P0"89L"UM^RJ1P]-'>]0*@QMAA'0.[]#OA,V]08
M>X.A81Q$0;(^&I)[QFX)&"UXLI66:LFRF98L%;W4?+O89(\W<$BCT<AW(T\>
M(Z!L[()HU-Z*=GS<N\ 1.!Y1C*_I&/^P"25MT(\YCMP@9F'!01<. GB3F*?>
M:=]TBXW:<4&..<38CDNP=<;;!!WB.."1UBII;XEI@9KM8_^4 L$1Z64<D5Y>
MO\^GZF+R)%2)NY@ \"M/QA5*O@"037Y\W50$[5\!^2@&$[?Y\'J>FXM1K+80
MC6<IT7C7_=@NML_Z%\<2:6 -97)DV(SZQ^CRTL@1M7FW$OF;[ ,4(ZI>Y*QH
M%;+.HUZ]5'_+G3$2^8XT3B,*Z7:"=%V!8I]+-R6,HTWP^#%/UN&SRA =N-[,
MPK%K\G*Z"!OS'6$L-%@#Y0J\C3W@U['L(*752]5G(/D6\+)::BW@I5:J*;S<
M$5[>B!*Y(?;7<D:RE1SH/MB^&#%3CL["ED<!JNP2BV3.R0#T*Z+:B&S<)PL_
MRL8 J)R:*3=Y2N%>8=A1/LT-6[H*0XLGUHIT#)G**KOAJY:!F]-/Y=G<_/:Y
MWS_O"#>*7BURXV"I(GN.16?E57#5@F?2^F"# %]FOFN9W(+A+CG>&E;>0FW,
M9@/8.K-6$<&JH2@K#*A'XC(IC')EN[[L)%[%N%^.<4N,ZGZ\[/:?A% +32@5
M&AP"&K1O3CN79P(-'CG^Y3E],S3@+A#3M5F B7<O@A7QJ!6%!=O @G[O2B!!
M35]3N&S[N%6&7D[B?(>8H:>K3D+;[B2$:=H+$<)5V;U9 22>L*",Q^TF]*Q[
M8)X/=L/()8X+V@%6E>QW#L-5R/ZQJ4H6V-9X@E4]I)2C8?.S"5+4_A_J42?=
M)%\0]S6Z=#$5.*0^N0:X1K:+]<M'U]?7QZEV6]POC48#_']1LF;QAJ/HEDY:
MJ1\E'E[I,&0B\*G5ERJ^C^4 [/1,>(RA4ELNK*;S9WEIN"399+Z5\@9OU([
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M28,O#R?^PG<X <PR'H9<N<&;=OUU<]WM\>GD X;0,H5#2+3*A'79=. F?3$
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M*Y&+52#[X#-&3FDP)A\PR__HP^F'8QP%;8%^R.7;ZDT7UL4/,#!//\1I7#&
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M+\YC;")F :Y8>=K61O&<_ICLVQB%0!:@# U HQVB5L5;0D\=!D<HC-RYX'C
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MEUCRB-W(033#?S'B..'A'A[,N&,X*[60BKJ)[<%/62&Z @_*Q7(][6X&$].
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MQ(GA8(0RCMJ%&/(%20%Q6%R@3SJIP>=#NI'0>%SJ&Q@8 =HO<K^(>+#[N9T
M[0,W<%*0GBL+B8""A10JD3]8PMH"Z0BPL*836%<R?#F 7V9BW%] T41><U,]
MC6V+0@O +S0'.4MLS*9\>])U(  AN$F2WB$/6I@XXJ!3NYI+48<7(^I*$2&3
M5W A\'/,?@R;6I-%4G$?^: HI7:])#,(^!1FO=F8H"R/P,6P A  <A+,0ICE
M^/ [Y0(XR+M#9)Y#:MEX)V\W)4J")A[<QST3B:1+YF$8KN^A5X1Q-!WQ GT*
M.I @P@$+[QG(WRA([&N>)3@#50&_&3MZ4(M*(U5:]P&Q8TA^(M&8^XQMSO%Q
M0#R R49AS!.2T,YW9'+0$J^:13H+L?4=RL00E\]72J1#_!I^:/QO;,YBR^91
MR:& MF3;#!0F$U'K#@2MR0U85&TM'^3ZG4B]DV^->;/K"R_3/>,OBB$//.\.
M_\1MB-ROM#A ,,/'A%2$E0-% LAG",9)1SH%XBP/*DQ_+ 85O3CD*D"G%NK[
M'.&D-68^O 30ZI8E:5$+"B>L\CJ"-;BD9QEN85:_9C*T&P018;(@LMVXY(OR
M4*9$6ZXWKEB!>)\-\DDH?#RA;<K!98BI;Y8S$RE)QJ3<H12F<X<?T]ZL\TN*
M^Y9(&Y7[D-ORO 6F;'V,R3&R98P4/=(J"-%/#E@L_"$!.;WZTCTK:JU95V9Y
M/^?X"=JCJ!QBMA(G-7%X+$FDX,V<A?$1NUJ28*Z@E3$%3DOG"(2:F,T1,\28
M>4F 8;Q8JDLSHE@-=*X+XP!Y:Q"ECVG&025GD!@D@R<+M\U@'!M$D;]8.#B3
M*#,/DK"8A'Z+)RTW&V\@8Z?ICZ:.LY#\R%&DD$KX<^9F@,]6P<G'YYQDH;0R
M[FNPA,P<6/-MY^),F&Q@Q+)P!1#%8'&)TNDWI2@V/H@%B7$OT\1"F865=D[C
M<N/&'9YDL!/93U!@ XJYE!*9=ALD^Y2I15.9N3"W:Y0_LX6=);?"LU)VQUWW
MYF].@X;KG$MOG37L$TM9UL3A%6B9+=L/DWB<(]>"@6E@5KI@L^+C? Z0Y!P_
M_5!KG7#.(JQ26T@(5*:$<>*XL_?+< FZ/!$;1#NA9?:RO".ZL"?!$IVE727-
M"6>6B8R[<$%),Q B)1PYYOCT?D;X!9$S G=+C4>8U8 =KL/Y)/4S1:8OV8@E
M\[A=F\VITO(B9@B?SG/@A(=P4:?\N<J?NWU_;O,1?VY>H!Q[.6-MDQ=(<M&7
MUN&\",PURA/V;"82>F;IF";H)#@'6/#Y2*8'SW@VRI.4QC!O(=&9L)2:#C!)
MF7(TQP]$9<)$J,$\J1]Y._)(FP;"GYIPY;2R\H#\3L0=-VEBXWE.;UOPNCXD
MP=%0$]H5SXV;2?%8*LIP$YIX\P*R,/LF"KR4G2!SM861$V=_I\QA'C^.Q2S/
MH.9LD6MX8[;BM2BO!7#$<LP"UW>D()MQ?7Z.#PFA>Y;("MY:";[N(R[\P](=
M@Y\8^L.J!QY'>"!\)P##%;:UWHG;XXY3VP5SR4\OE&<)Q/$#KH:E8!'O:LY'
M-SL,N;+4:N)K%D_TF?LHY@ (;WCB[>*6&KI+)DD:[FPE;<)% 8YP!?5[.L S
M#ZEQR_6:E!LY$$[T*;_=&,=T,U=U,SMZT:HV)A&>O>=.XOP]T$"&0F6B-A_Q
MDC*N44E&^S!V'<C/Q.^+]6S,V!6D$/#L)_3K,%1V[ER4JS9;Y:\"[23"P57X
M8J&$+[@^1)0YP7SY"H>-N+A&1VCJ;;PR!U;+?7@8I\$FD18V-YW]"AJ1,;;8
M7>R/8<Z=Y;O23D)%QHA;C @#2OHB_BL"YI++I<(YTA=IV#SD$L]S%@Q#1)8=
M"FP;]2 KH$$X<S$M;6*9YZ09S<>53D\.E0E%7CM-S%(1OA%:X_+;%Z"<CNN+
MQ<7/^,(>%KQR'@G>NW)<QAEP$YRCP1F@R8 SHW\02PX1K;AG8L'[#0)GX0:?
M26'#$NL#L1RQ:15Y4DZ= H5E^)"KF,#:8,'"PA I.<R?I/*-^-CL^"61\(K@
M)=M^D33DM=4L]*<S_[N>VK+6\,,//VQN8SO5ATZO+OOMTSZ89,V3.-C8'[M1
M@!AU16]7I^7E90<=VPH"2FX<%[,KZ^564:]I1:U:;I CM,3H<>ZW\!_\N$-.
M;<JF0);-<JU8T2K%5J-1PQPF61FZ>A_YL.R>T':C]4:9@P=M#K:VW.KIX6I#
MGIVPW:8^#R[H%'07-PY?W,RE[,(JT:-4Y*6=^5CM4==)"A0Q]XB[]D!Q*@9C
M*L:M9[#8W:STLT,CT(&8N9I7SBLTS7F%YJDZ1M^:@+EUR>Y)SP4E<L7J6VL6
MU&GU\LF:Z]96K%OT_$T8O&_",7'+W O8N_B/$U#(/9M.WV%?2%@&?^AD_@,9
M^<?\>^+RC.N6RH+SAL!20S/^LKQ<XI=^#LWE:[5FJ=5LK+Q<+FDKKSWTVF9)
MK]6?]=:'K]4JJ[_Y_+56R_K>K'6_X-I:ZZT_<ZP5F O$$7C4^?>;RIN91L*;
M.[_3O6]D@>"PW_,2?;C>"ZL*S4=[W64P#KGI9#^M=?8C&,CV=[3$Q\NBK@:[
MYX ='(ZQ);/)3%39;K#1$?>95,J%E=M=/KXR;O;-RT)&L,&= .<2<YG6A\W+
MXOA6]OTL-)]M28H]K*2!'1&N:9%X=?MTTJCFO]1^5Q+!8<*M\A+\X3!!HU#J
M)5 J[ZJ#5EZ+J?9D;0KW_VT1,5X:AU[A)Y^&@03_VR@U:CE&QNMT&MDB,F9L
MJTQVJ;6LN:D?U]E(>@,^/IRG'30+&DZ*R-*^'L"U)^SI&12DL&%7.Z@7:M6F
MP@:%#4(OJA0J6EFA@T('O@.M52@W&AM'A\-3?:YXAEQ<*;Y2$=<S]YB)W+G#
MC4I-SQF?.!"PUA18-\#)"F4];VK.00"VI>52/FBM'$N'OAORXORUI</*YK!K
M.^3V YF:A5JY\B Z?3\D=D;;!W96]4+KL;-21[)EZZU:J%0>EG+J3+9O0K5:
MU=V>B92?"^FE+7X2K\.Y_CH^>2!!K*NDK5K<FVW=<-9F#F+O;ST\_\HIEIUA
M8696:.D@[*H\.F(/ K!:H5FN*\!NP!-0:%058#< V!IH]:T\.EER+B1Z\0#O
MA:XK!RDOM$*UIN3%9CS'C<U3WRL$;+6@5Q7&;D1UU+? "AZ1%W%-DN/BA(.'
MSD+=.7_GX0GB&V;;O#OJ2,RY%NTXS(GE6+R[BG7'#E0FUW45S=T(8"NUAV,/
M"K#/-#5T387)-R*36^7-LX+#$QT\D>H@A4,C;SG8!P'5>O7A6)L"Z_,$;G/S
M63ZO$*S-QN:Q]3"3I]RE&.$Z:52'E5I0+U1K#SO<5;;'UGU:S>;#:='J2+:?
M@%-I/:QKJ3/9]IE4"I7ZCA/55%+4Z_CDP25%6;REW$':Q'JA7%6&QF8 JRM_
MPT84OI;"V,T8-W5]\]E$&U4"U*T'+9!YB:\0QN1(>B&.5:;RUC.5<XPC76Q[
MQ8(P=E(5B,,.,_WLJ-&H'RL)^+(@K;442%\6I'JA6FXJH+XT4,NUZB:!>F!2
M(:TY'*Y$T K-BDKOW(1EU%0Y91O!5[VI4I\VXGNJ5C;O>U+N_-?QR0/Q'LBY
M, ,V=/EX>OZOD'X[V&I6K:S\SQN16LK_O"&,;>H*L)O(>RV4'^D;E'MU0-UZ
MR*+YVG?OK  '#P]=__!%LZX2T3<"UBWT17R%8*W457[_9HK<MU!0IVSTU_')
M U$$+EFX(MEN73I7'>E?WIF8OZB"PH;=B:V&P@:%#8G+IEK/6U< A0V[:V70
MVEX7G(VKM!58G^E&. U\:]J>^N9!JK4=ZCNPSH!X#/!V3'VFDE:WGK2:[ZX;
M[VE@&<KHR<L.:J7<A:(4,NQ,RRWI2LE5R"!S 4O5O"4#*F38F3=$*VF;G\EW
M>-K.F65'(3.5OI.7'8"^D[?9D@H9=JCO*&10R)#H.\K?KY AT7>V,,E%91+F
MW:.66\7R#_X/9A8IK(B.F/"V!B0*F$DLA\ 2C<BF(>8:ND/"E&-6.6:?X9@]
MB RT6B5O+LX# 6O>_$,' E:%K7N*K8<G%%;XKPX#(ZIY,_X/ ZR/C E78'TF
MMJI:FCW%5BX6?@[IP&;P7].Z^_47^)\%J[^*8L!S PM-MG<^L_GLJI-[RPS'
M<JWII\07WI5GC]!!X"*S7GI$P/777P:X"KE)_G/Z?_'5EOGO-U:=EO7!L%P9
MUEIZM5%K-IN:7C/*]<I0-XU&K?R_NOXF?FCLS\ T8L6!S^AMD0Y#YK^C]CV=
M!O-KGEA.#/QZHX3[77NICUR+OY ZE_]&06@-IR^-5=IC6*7C7MH7'SN7I->Y
MONKU;TC_MV[OC/S^N=WK=WI$+^M5\J%[V;X\[;;/X::;S^?]FQ7;W?*ZK]&3
MH)>ST&3S2VID@W(R8@[I.D9IVR#*7L^IZ_ R%0IJ$7E/;>H8C-R,&0L#4B0?
MV^WK?*SSJ.L0>*L-K"$X?A(Q ?M#5K60S0C+MJD7L'?Q'R?Q@$'+X5_G#YU,
MJ#\",I?L"6E\495%$A67)?FW6J6J5D,.(%5G^6')'$J<.2RP97&M7BVU]-;*
MR^62MO+:0Z_5:J6:UGC6:Q^^!C;(9A:['@S6-$^>X!++D/ &P\:46Q'QS<<(
M04Z(]$(V&3"?5,K_O[UK;7+;5K)_!95LLLHM#B_?(NVLJ[RVD^O:9)([GM36
M?MJB2&C$C40J)#7CN;]^ 5":T9.D)#X L*M<]GA$D6#C -V-/MVMM'/@*8(8
M/N)@+05]5PK-H>*<O@I<RXJJZ!I(:2IA4B:YF4)@J_GSE'H"&OT1^ZLP(J;#
M04U++A)I]>.N'!^!L.,B?9]EQ/2Z!'7\O-EQU_3#*DW)[9#/WI##>)U\QYT?
M_&S&.D@'] ?\URIZ].?D_@?E68"9T=<;>(JF\W82!FCHC:>C*5X';5GEV^GN
M4S_$*"5. =GBB..>R5LM>JR84#"I'<$:%9WV8.T=+]#Z2.Z6I)&D9=_(@G,@
MM-J*[6/KL.#.EUO1%2'8\:>D7'FFHHW;IRT/<.49BJ-QF?\F0#_UL]>=9!V)
M#4<9.]!,G:LY,37%-'ONIGX\^T.WA4O_D.2\]?<T69*A/"MH.??I?A6'[ AP
MN2 /D=<]=A3=!INAG2IA'7#V)%E\G^/<CQ\BRCLI[ 1Y%YSA*I[!6ZJI%)(U
MB9D.2ZZNM'Y.DO IFL^E7&2ZJS@V$-%;DJSAP2([Y^@I3N(!G#[IQ*ER>2L@
M)H5D/<7I(.@MR9(K3IV.K[-&3C-$">/7?TN^P:\I;L6VPMGY&:!,0)2-%=TN
M9Y+T=2)H#*KD=\/$U&XP=9R;^DOD3Z)YE$<X8Z>)7_(D^'.6S(E(LG]'G_Y:
M1?FSS,S5^>O[ WVU [F_#X)D%><96OK/+(6+@LX/@G2%P^W) #8K+V^@T]@@
M;\<4 (<>X>!9O)VMB+#S;33.,DDW)<_F2?QPD^-T@4(\D3.28"IV!^3G 9ZW
MZ(IE==:S4E*Z3XF](3^_Q- 4LZ)@.F=G%O+/B>XJI@><'^#\;'OH\AL)MJ.X
M%0=;7.PVXDG6,15]W%D?0)F6VA03&R%$N?_U3#-!/)#HRIB[?%4I!&LH9@?;
MFG2+;PAKSE ,%PAV+0C64IP.!"O)FCN@_LB_['2O_</+ 2X[HNJ,SKJ1B+[L
MBE.H;"O4^OVWKJ&/W[)DCKV JRP(&2LV=WU<I1"LHQ@5>6*P]/:6WGR/]5!_
M*0)O2D#>%+#S>)@&V5'&+3NOH:-[D<EYXBFJ+T6SM&259SE1463(4EJ%T(I#
M[%9"\O2,L+]Y!STC9.X9H4//B-/CH5TA4)Z@VR2^83_?X2") ^(DL0:=&1^C
M''VDG1W2C+8/K>H<T?70CM3-WE_'NYTG]G1(40:<&FJ=MK8@NY2J%3O5N;TM
M;%=UO.;;1;BJI1FMM+8X_4P8*W]C[:9CB,=9JPRG5MK._2S%&"W(=;,,X3C$
M(34@&N\C(J9P;LEOSI -KQT@>I0@=!>Y6&YF$^NNAFA$DPO@J0D\-7NXU<J;
MC6N]&?,Q@B3+:1Y,YL]/9OP)<@:^_]9R'8'7>SM3,?5RZ@V$60!B5[V=KKB:
M4'5JSU+C4N)+''!YRMBZ$%P<(FL0X!(*7[9BFN7DPZX"Q.?D<]9+J^[1E'P?
MTJ (K8"<T1/L':.2PYH>(EUZ2?JOH1J\X.54"9*_5E$17;QA 4D<(OQUB>,,
M9VCDGVY[R65 N-X[CXCA9#L'KP9!]FMDZC@N2+11B=J*;0%*FY6IH6A:JSB5
M4DE\("/QHYA6>$?!S$\?B&Y8KM)L1=LN$"LC6:4HQ5F>K@+R2/)^14]68GO<
M9/XC^3^-41,=P^@N@N72U),0XTD;;X&]U8*RABT0D"J"9$=FJ]JZI>I#/?JJ
MZ\+/)1[K-86(>*IXTX1?PM-QF^3SX#@>S$+OLU#J_\ \=.DS658_\R!-A/^%
M27Q5E%_^$(8X\0M=L2Y-<.,P/@;(XN?5=$4WRVL# +( 69>\FJ48VH6<)$ 6
M(*N4[69XY4F6G1B*FX>MQV8.*M=[*,^4QBDX= B03_Z@)4XI^9KF:9(/EFD2
MKH*\]H&8< ZFI:FM%LOJ_HV^:X)D(_",&F.84;EFU-+55DM3P(QVOD9=M=7*
MH'W/J)1$C$&R]0Q#!6I9PX%&335 I,VBU 24-H]2FS=&!?<J KAZ51+2VC5\
M!KI:0:H@55&D.FK9_)'FA/(X;:&)4TJ)"#+ZN.)LI+701]\^-M"D=E#0$QT$
M4,"/9/2J4S5 P1!0,%8OK+ O.@H@#C^<9TICY3(+-\49]M-@QHY#0OR(Y\F2
M)J6\G*_7\!=$)B$)0S6BQ%O>G&+ 0E]8T,:\=; #+/1&;K5@7P LK.FH'>B(
M =2/JK2*H*;459=*&8(L9ZE,Y&2IZ!I$_QL5Z,D4;)#G94GM -"&&3]C?F*(
M@F@&(*=420C*\X!D0;(@V8U5R9V.$;"DU-E'^W)')TM<%9[2OR6?!*@PU?\<
MG':)8!(ZFP2H+=442?/2$#94V! @I*$K5D5XBZ<]"Y E$K*T,2 +D-5&2%YW
M 5F K%8"_)>VOH-Z4_!,X+F>=A(&68.J,H=+<%[^\([.=4<M+T@(,RK:C+JJ
M 3,JU8R.H0:5<!R.0;+[-!7:4 E5@F&0$C5!HB*M>BG5 U#\JB0$-7U JB#5
M(4N5+\7"A3*YEMH -:GV/>N>6@CU[7,#MVKG#'2@=6@ !3M[07F-!$#!$%#@
M#+5*(<3JA_-,:2Q?9O5F>$X^>5#0 XYQ2A-;B/7KAXLHCK(\92<D4)Z*L[U'
M5QRCU<#SY<PVP$+G6##M<@,<L# 4+-B*H;=*,0(L"(,%4_&T]G7$ ,I3G6,@
M0:6JJRZ5,EA9SF4)Y.2R0"&@IC-86RW2,$"!&G:K?;\&*%'=;+4YG93* 9@L
M51*"PC\M+EC8 0&J(DBV9:@.I$;5-4?]<@<NH4H/3 ),0I5?!+/0G;ZS3Y(W
MH6+5>;3.!@+<4*Y#@("'KMA.><"#I_T+D"42L@RO)XXK($MJ9%F*YP"R %EM
MA/_'=D^]HH$0.[!G2N,SG.TO#+..E5>1ZR$XEW]XQ^N&5I')!S,JVHP::KGV
MAQD5;48UN6O-24GO&"3WCR@3X!4T+-%6F54#E*@.M=;$6O52J@=@_U5)"&H#
M06%$$20*.(4:5J*1':"<U?ZQ9GGI;VF+EP#S:@<%4-1L\"@P="AJ!B@8[E[0
M4_2^\Y#V4!\HC>'+C-Z$V+#$M(T?H% 59[N*HUAV>0N]WEAL@(7.N8ZNVVIO
M)<"",%C0/<7T=  #@(&"P51,I_VR90,H575H"$%!JJLNE3+JN <:&DZD1[_2
M\E5'NN+:#L2[FLW5=CR0:*,2M17; I0VG,RN:);%3P113 51V1='3J4!%0R;
M%2CH"RBQR;5 05-<JRD:+C E'H1@38) ^18HE+WML%03Z(U.B.]H%$J9207U
M1-M;M'#2TFQP%T#: DA=[JK>"J-9R)UPNI5KBZ74$*,QI#$V[' 8D&K;\"[F
M 48;QFB[$AU(-?1JUN@Y['9-1(+[2%<\[V3:=NUW[6WI2C<;IGLR+Q=FH^M=
M5M&LD[8 S$;'LV$J^ND>(*W/AC3Y$B^)PK5S)J#:JP 46DNQ[/*:C%!'&)!U
M61UA6RLO;0'( F1=2ONWH/@Y0*L%:&F*8??9"P2JGP_GF<?G6A\W,]EP*0B=
METM!Z"#T85P*0@>A#^-2$'I?0O][[A/;DOP;1H_O?B1_[7L+NDJI-LNDJ!__
MAM6/CQ[QVZ<HS&=K3V?[>X4+\D9[_8H_(7[-*C_\2N&4O?MQ0L>Q]H_8K[?_
MGJ6O+_& ;R8I]O^\\:<Y3M_X\R?_.=M]_"**-UZ8,V9#K_W4BL\V3]CRP6@D
M-YH^-^Q=ZGJ5>VFPK(=??_YTB^X^_?[;W?T7=/^/SW<?T3__>']W_^D.&9IA
MH9\^W[Z__?#Y_2_DHB]__'+_Y<3K=CSNWVF13\,X-N/;\^BG#V0JUVC:.\.@
MI4)Q2K<&"MX]KXF\QMQ?9OC-YH>W890MY_[SFRAFHV%?>KO[  J4/5^:/:_X
M^!5#JE;@:!V%63]Y_;'*/MIS\8O/;%=U//ODQYJJG_RL[+:N:FG&17<M_\PV
M3S\3QLK?6+U:=P4M"Z;-,"X%H?<G]%/?V6CA.(EQ^=WARMTK:_(^3LZ;5X<B
M4MA4G81/G'ITR5F*,5J0ZV89PG&(0VJ6?\'+'"\F.$6FIC114DI,X=R2WYPA
MFVL1=#0T44ERXEJ"U$6J@9]:[SLPN9G-EG*3230 J28@)0W1<8_D&,5!LL#7
MTD>EI'4(Q>R@!;TNK,G/)VT((,8AQ(SRTL2"04Q^?(D#+DOQ+MV_.$36(, E
M%+X<Q3'*&RYPEBO#6YWM6G7.+DH=K5PHO&&))8="78\6Y&IRUPA#!KFRA$V0
M:PLI0+I>GJ?1O=K@0E?43K&$TP<YK"N+EA.7R34$B/$&,5.QM N3X@!B +&:
MV7&>=V%V'& ,,%;G[3QE;%Y8D*#A<X@])A+D8,KX3&F<AZ.. _(SY"/R2QH_
MIASN9(J6:1*N@ES>KEV&K;;:(++[-VJXT;IP,VIJ:KE*@!D5;$8-76WU(!-F
MM/,U:JFM'OGW/:,#"$Y)W\_3,%0XYF_C6*#=S7R@8C5,0&L[:&T_-CT ;3'(
MYIY:NZ[E0)<DZ(]VI-I^['V(4FT?JP/0'D-O^-F%$3*\Q:FKY16'0:J7216,
MGC9V@/:].QD5"70 K8<NV G%-/Z&*%7 JIBVD,SZ91A]0%N.K ]T[7EJ.4L2
MI,JKQ3P\J9K<A4.X4 YGIN@TP;23J_&>Y:G]Y1-W_[H-\W_DPH)M5!BC@(7!
M8,$:5SC1@(7!8,&N.EJ6&0N09C*<9TIC #/C-Z+%"''V0O51Z&%\#?=!Y.PZ
M81+H1N.Q<ZK==6\)F(""SE%@>X""P:/ 4"S-!1P #A3-MMK$@=B1H..VSAYE
M[:C5\_VWMGO@O%QG7@[I4K%A<WRQ?=[#"4IBY =_K:*BM]H-:\>&*6=^DJ/1
M5,JPXO??NH9NO(5P3?/A&A,H*(!7<20[=GFC.7*A.BK"B^><L$#Y;A$L\))3
M&9$*=P.F^'FUD66, 5. J>Y.C !5@*J+4*4KAM.3_H,PZW">*8TC4' ,&0.]
MX!="B)6C%] 5U^0M906PT%/O")<WJC\@H:]=P>C@K NP( (6B!=EMI\T+W;T
MK%;0M=(&$B;4V?NE8J.E(M:ZR<*)P_W$38B^<J*+9)#LR-1-?NA4,D@4L-H:
M5AWM9'B@ ^LCC++EW']^$R<Q+I\$N'+W2AD5]2W.T8,?Q1F:ILD"8:*0\V>B
MM1_QQM@;/4BIBT>ZXO!$P95#IF,-)-JLKO# KFEZW9N:#?I7P"LOT+^ZQXGV
M/7ZH<I_DM,3JI4<K-=*/Q<L]+E?,/#$=))\'RSVI>F 6>#  8!8ZW),\W>B5
M)R,^=^*U1E--_@10R$2(J!D75HT!:B+@J@Q7&N *<-5"::-+&Z4#K@!79;C2
M+^R.#F1J>.: R=1K@L@$3Y,4;_Z7^U\/*[,"9ZZGS'9%UWAK- -8Z(M+ZUF\
M-<@"+/2U+[@&8 &PP*I)*)K6?E=+L0DX-8M9G3*'H*(5L*PK./DOO0]D[M!)
M3!"/-[4CAUQ-%TI8M9"(J&@6;^EG,LB5N*4ZF!P-J(U:-:UD0 RD-+2V%J'X
M(>!5(,GR5_Q02,UQ"5-5.*Q HDBWW%*0*"2*<"'14LYG3QI"Q'R&^A%>N4G$
MIMLG0P3HW-M'749%%1B8B\YX4XIIB\/(DWLNB,;K=8^2AMFT52_^3'83<#T%
MB':;BN5=V#<96,2 K/*@QKC\: J0!<BZY-4\1:\([P*R %F7O)JK>%Z?R(+<
MA^$\4QH/@7D'RS1YC+(HB1%Q#R#W@<.]S1A#Y@,@@2%!YXUT"$CHR4=S+$ "
M((&=EVHV4! ;R'HX;0A!UD/760^ZH1J\@.=4<?D-/A">3G&0HV2*\AE&_B1Y
MQ#OAY]%,RN*UA@&,\B$8^S)(E2A)C3?360:Y6E;[G&LIU<=O6ZQ5ID1V%$8D
MI<(8F< .;%97M&_W#T^H(\L"E#::>\BEAA"0PUK_I/X<AEBM0"9OF-(O+:#7
M3R19^ODPO/+C2)B/CHD63KEI //1M9]T(:&JJ?F0)F;]PFH].VY]':(X\Q_/
MIO(<O"37R\4I-QHYV[X 8*(!S-8O3+T!@ ' :A8RJJA+"! #B%T),;NB)&Y7
M5B6P7@?P3&D\".8]L)!+AGRTQ&E [NT_8!K WTV5JWNV)IP[ZJJM!D.[?Z'O
MFF#G"#RANJZV2AN &>W\!$\M/^&&"15L0G5;+4_7%7Q&@2$*#%%@B )#=/N4
M36T_]C\\16*I4.>T#:SREE C@U3U#G8 *97'(/FAFNH!]:Y)B6HJI&BT@E.@
MB#:,T_:37H D.C22J%5QRLU9!%;Z^:@Z (/Y@/D8\GSH?>]7TH1X7TBBC89Y
M)4.;67'BT2;<^@Y6P,ZSBP6GP@ '+ P'"U9%Y!FP,!PL.#V:)'UC <B-PWFF
M-)8OLWICG*]-7"CAR<<+&(IKMLK^N9SQ#UCHG+<_!BP %C9-/"HRM0$+0\&"
MK7AV^_O" &B:K^8/T#*!EEG9>/Y4<RS63'C#V8SVR9PR$G!T!VI/ME&+A3=K
M3P:I6HI945,%Y'IA5K'5?J54*37+$#F;)F_>BPQ"'1E0*+7A\EN TN91ZD!?
M^JOIFJ>/ZN4/+D+-2*[FPS.!+LO3?! /Y]*6EC CK?E&?%1<$C]0_4+1K Q6
M0TDR84(8IJ(90BEU@)AH$#,4QQ'*3@&(B0:QL>+:0K47 (B)!S'+X\.2!'KK
M )XIH-=P?-W<)GE!ZD"WJ\4$IQE:^,\H3G)$7@&%*TS/U-)D%=/W >+'5<2/
MO^<^ 1;Y-XP>W_U(_MK?*G25QN.621;E44+V'#SW\^@1OWV*PGRVGK#M[Q6X
M>:.]?L6?D'UME1]^I<#6NQ\G=!SK662_WOZ;WCH*_^.;R/$U8S+5S*GM&=;8
M=EU7-^Q <\RI$09C6_M?P_UF\Z59^OKF#_AFDF+_SQM_FN/TC3]_\I^SW3$O
MHGB#0&?,WK?V4"L^VSQA:['1D^%H^MSPRM+UJJ5E,%[,KS]_ND5WGW[_[>[^
M"[K_Q^>[C^B??[R_N_]TAPSBUJ&?/M^^O_WP^?TOY*(O?_QR_^7$ZW8\[M]I
M3J=A'H-)KU(^./8HI+QXP#'Z' <J1X X/M0B@39!+R<U=SA(XB":1SY=O!GW
M+S#Z'"-RUSD=K(+PUP 3=;DDJC.;^2E&H9_[/_#_$G_$_BJ,<AP>CK5ZZ^EX
M+=[/,)HF\WGR1%0*8OH#+5.<%=$N\F&0+):KO, /*U#"@.7'(='A:Y2%$=4(
M(<)^&I.[9'3&$)NQ73;GA7LLS0+'*;5QV>AV;2HBIKF_S/";S0]OPRA;SOWG
M-U',WI9]Z>W"3Q^(7ECK,ZH4]BPD]KSBX[6^\!Q5]URJ,M9FV/K!:VVB,FVR
MYP(4G]F6ZHSMDQ]KJG[RL[+;>JKI.A?=M?PSV_9@K.*,U3O]Z?9=:SH0)^U-
MKXZO42Q-CF(4][,48[0@U\TRA.,0AW27^4+4"*;.!S(UA9E&33@:4DO(W)'0
MM6 ZZ@I7'I)P+4>J^6J@J-;[#DEN&]NT65=?&O$ K!J$E0"':%Z]0S1)(N[U
MWE;40$*]MZM.+(=8%4#LJK<#4@<'DR WQ*I+(@#$ &)7*LK>>4.M1MSATDLB
MWYOCW3B)<?G=X<K=*T&P(%BQKA2K\DD]K?;?[#\XO/')F&@@G 7*BM#:)I#V
MZ?<O)\^ N$P_K/?JM@5ML$"J@DC5A%(58DH5;';N;'9Q#MH_GM; <( @V@&"
MK1I"9>,"PL1#F%VNT !A@+#K0CFPA_4^!W(CS%*]\HZ_8I^R"Y+O-91G#I.6
M>DM^ ZS4JP4$I%1@#P(I%6 EBMR E I.@!A.0'57$_ S 6)7O1W4Z.%@$N2&
M6'4_'H 80.S*74SN,E!P:0,!;F"B\<Y#J2@*#.P>D"HW4@4FFJ!2!47-NZ+F
M6#O79J*M:QH="< -R:UH0@H\[U>.:M7R;!N00Q^N+X!X""#6+=6NQ68"% .*
M^46QKFJU&%. 8D QOR@VU7J]JGI$\?&BUL*4#]5LXY+RH:;JZ&X;]2B=R[Y9
M6H_25"VCWFV;]<P(Z%I>-L<I'2/_=%/@J[S8(^^]KF+<_:L?WS%HJ>#M7IBL
M>CSQ4)=I1-8'>1KKCIG$@9_-D+](R*#_Q>H&HV2*HCCWXX>(KD _RS#Y.BTA
M//6C%#WZ\Q5=EWAYLUH6USZ2!R1DU'[PURI*R3.F:;) DU5&!I5EQ:^+@O29
M>HQ<P^>1BR0K8#+8%?!3DK*:V/E!#55T2.95V*4-+IB2-8 V(XOW>;27#VSK
M 3>;"X(DV[J<7)2L4O2/)(W^10:]]877 16B8N7"JX=F=BDSV#<ZWC<"V#?.
M60P6N_",57'5@H75T/%J"&$UM*$:,KSTTT(A%-@GBB )(G;A4Y3/V )(<9:G
MJX"\$)$8(NY>3%0'60?LJBBFC2S(W>A385UTO2XPK(NSM$3-=1$MEL37HA>@
M8.:G#VN>3Q3?+-,DH,;1W???FN[;C]ON&;DRIE>2)4$?\NJM9=3:"LC B&39
M+8E!%85XO?#FD3^)YF0]X4Q!$R*8?05TCV.<3*)$86V5MO508;"1]]);-B']
MHHOUOE284-[_^C,R+0W6?M=K?PIK_TJL1W$P7]&+1]$/U!W"5-4A_'6)XZRX
M;Y&Q@\A2RW <D<?&24Z7>):M"N7WJY\&,W9[=OTH(G<*\21GE_AQ@#>*E7Q(
M7IP,9XKQ@8TY2:.0+*<@Q6&4LVO)6!9HGA!=N_GE WE7-FR%CFJ5IL4BI:)(
MBMY3\R2C&IIL-O2>V_L$^=7:C(5EVO4R?8!EVH:*IA#_3QS]3)0CP@3I^?/V
M^>CKUUO6C'08MWBU2%(?W9/E[2_QBL@^VRAK\K0ZHR37D[UGB0/:8'3^#*NT
MZU4Z&^PJI8&*W/^*\'1*X$=5Q3[P)SA_PCAF6#_L9TAPNYK3]H?^G\SX96<K
M0;(B[Y&O;YVGV&?W8M]\T7WD$V(#XU'V [G2)Q\NE\6BPC[1J:\CV%C4]',B
M,'I@2;_[?\0AS<(HH!J.W$-%=)6E_GS^K+P\F9JLQ4OMK+5"\5-ER>Y;*_KR
M$EUY";@HZ,&/XN)3HGLS:N@74J*7O!H9FY6?8:*VF:'/OK*V,W:,@5U?FWD5
MQ'RXR?S'B+:*7/O=9(\@+Q%B\OV0/?-IAIEML7Z;%7TN:P&*0W(S]B9K&;[N
M,@<R+$9U1-";26*W2(AEM/,M%7TLVE*3;V;4[0F(;+)B"@I,;1Y&[\-<AGV
MK?=1!J>UQ37!Y$*\^1_Y]MH%NT2?//D9LEW5^8Y]1W=5][O=[59!M&^GGQ9S
M8!BJ5EQ*?C*^>WELD*3T2PGKO4V[=D9)F&W62V&)/6,_A;V[Z[T[&O3>?<Q$
M(2@.R C)[K3C!D1D:9"566"U /"68\(^I6V$"Y^(G2VP);GI5'L$V54]U"U1
M.JB;^C?OH(.ZS!W4K6,P:7](9[=)[V4\>ZW/J5;[0&/&/\V3IPSQ,<;M=N>G
M>H5W/:2KFI=S3\HS5-,;7T+*LXGA9!@M]'.VM4OY?*5</Z\%KI] 8]4UU;+K
M-<KF9+!FDR3*-JH#-F\1NK6,X1H-JV6LFUA/.-5U$X=;,K&>!&O6W1Q0;;O:
M<C.;=5)E$@U J@E("9#,K6NU:R4RRNHR31XC>A@Q>4;)DC$FZ+$H/;9CYZAB
MEU*L*0U12T35?#U3L<<]UXBZ)O\/0"8"R QE[$"MN[YG07*0.<I8]P!D +(V
M7V^L>&;/M8<E-#1'JXQ%]G_8,3F+,'ZYR?DB "[+>]64P\C0M8,@ZO'I''S%
MM-HB=0P0:;,B=2P+1-JH2%VWO,@XJ(LSU,4TBOTX&(*Z,!7'UF$I-JPP%$VS
M0:C-"M4E0G5!J(T*57<5P[- ;]1'X4<<I-C/,.70%C]1,FU1E8%R?.D/E"3\
MZ,\ICZ^&TKC.9^<.4B/#.^F <'9H(O]D6)Y0S8WDGY"13@]]8'UP,AW&6-'U
MGOM,RZ,</YS2@LC/T00_1'&\SFHM&.M2>E2>8FK0#J*-Z+*E&!:TA&C#"] 4
MSVK?"QB@9,>*8Y3'$4&#U-8@F.8WG=(=$  5+P#J*9H.?*&^9T%RD!&S85S1
MGPM0!BB#K0Q QCO(>-C*CE=!T.UFRB!L#?](WX5VZBG ,T\^LXW)/LPW:^(U
M*^X*Z8.0/@CI@Y#KQ87<('T0( 7I@Y ^".X-I \"R+J.^$/Z( >S(#G(('V0
MAUF0'&20/MAHX'D9Y?Z\J.0;1N2^LB9\&/882/0-B]2"O(2&13HV('^FZ?P9
MYR3O&'3!MJ1^H@?G[-1A.D^>VN^6+H$M)6[3^-IG$Z9>SI#LOVO\-28_X'@8
M.#84NUZ^ ^ 8<,PQCFW%J\A;!1P#COG'\5C1QK6.HWO$L63M0:QOWD%[$)G;
M@]C0'N3T>';;@]!\&M88Z-/O7]#/JRAD?4[S!-UN>L+Q,>J=X6VZ>/T/]E/T
MJ>CA]1$':^J67O0*XV/<DG<5\52WZ-]P;E>1L:7:GMU&FPJS^5XECNK9;=S5
ML;TV[NK4&ZN(YW7'^4]LGPHC:CR$;"-[6.\45_#LZA[SBF)/BV,1NVH%":A]
MUZQ?TE]-.7W_K6OH1ATA 7"[20%3;0=2O6OOVO\5)T_Q?N]8/TUIBUD_?VE*
M_+?OO[7= XE>QYCN\-+SYHM!8JR.;5ZF[CC2W[\V(KW9]"E]:8$\\AOIX2IR
MJ%77U0IF#NBP,ATF#0C:KU;3DC[8<C/7M[BAUQ/W8EPD__4@4)H+4'1I9_V,
MUYW8M_JS[QW[]+7_"['R1L2)/"S[.VBM]AMMG=V[H2$$>C15-SK$CLX1=D[D
MDVZ.2]LYABB- 9T.  TD'%A7 'R;"YYJ7!$(K"F#9FW-AD;$]UY7?LX"*U/Z
ME6EHJL;ORCP>G!<IV/PW=#_#Z,^#XR _Q6B9XHSN""&*B?6?3&G<+TK1YM A
M][^B:+'T@UQ!3V0@,^0ODA5Y WJ4M%RFR==H02Z</Z-_,U33HZ4#438C-SX,
MQE9*A7MA:F-JU_L_,'%N"W*9$BFDY%&T9/U\%6)ZN%94K%\D!%K_>@D%1W'N
MQP\1A:Z?99A.0ARBJ4]$_NC/5S2RB)<WJV5Q[2.Y>T+&[=/CH)1U44&354;&
ME&7%+XLSHDQ&:3/H_K9*T4FSCVP".".BSE_$3H/6>#K%0?X2=]\Y_R3+_0&G
M19([?BQ^-_-SM/"?41($Y&'9:I(1QQ<7$"<OD+$EDM$5P7H19"NZ"';%KQ23
MR59*E+)G*6A./GM@$Z^@8$9FG8R5S-_67),A)N21 9$"V:3H(\F/612RY'N*
ME\E\?8<")J5W.?36U5/4@K*(.!]DB7NR[=R1?>4H8X*/D1\.<0"L":Z8$;:C
M7\B,</5Q*\P(JPVV@=L*,Z*EN]9CG(@88SMNNK+=BAI)*=T*&CB/D.)DWE/+
MS?DKS?(>WNB[,Z949*=;"OCI9"^6&G]21@?N-[LH,0(/?55B-P2KC':2]"?)
MX^!W6.M:A/,V^[#!"H0^^UK]SC?ZY#%/7Z)F+9NH+>?4<;< =*MB!?2:4];[
M KH@F'6N3&39_ >W<JITQ[!7C@B9H'^?).$S^6>6+^;O_A]02P,$%     @
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MWT-$^_A'YD)<Z'K\ ):ZA6*[7:#2V,CM?. BAFF@Y?TC.A[C-!C2A>K]Z7P
M@CR0.QRS8Z2:NF&F*2IFS,&!^18)S^-";Y%IIPG>N#J"=SNSEX:/D=5#<+*J
M7VE6*+Q*^!V#=]6MQ=U$A,H I](^;A=.HA!8A'CYH1XJ]4:(S+R-%RGB;<6!
M (79 %H "QO#'+ZX$4$TH=W(K<M?^'AR\'Z[O(R\HQ(!UO'NL*&F.KWE/IAX
M<E+IN$76LSZGO;6HTQH?(@TXEDB1,2[=ES'XF,!:Y"S'M$]W7S\DVH-DU5RQ
MP- ?4.WTN!JQ#UCIO/6A]V%[Q^P&@ ; F5/#?4 - -(CI'M\(A,Z9@+0@OZA
M-0R 6PN$\7#4 8RZH[<;B,_![(TS5D=?._;QAGGMF"-LKT6E%)'=%X$$+@/B
MCCB$#B.I50VL,;?K#[&$B3X4ACN@LX$.$] HR+ \1DKFM\\C\R!'#CAR'9Y"
M [[PM1]%S,J#J8+)^]@+UI-$L2JS18HL7]1Q#["I"$=$.L!M-EI^Q".Z(:6H
MM^TICJ+R=U/7/C-4(J;%ZV%\A!2OCTIF9G&0(FME/7M9RB2;)AQ&.' _54
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MF=+HBU ,I G#A+[:"G4!Q>XT0A$YX.:S\F?0LF".U#8L!$1.EWN+ ;1!>U1
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M"]$0QE<3<U5:?(XF![\ 4$L#!!0    ( ,& 7EF<-QJ5(@D  &!#   5
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MWB.$D'Y^_6)YN7OH_LK"ZQ?_!U!+ P04    " #!@%Y9\1(SL<0-  !E=@
M%0   &%M9VXM,C R-#$P,S!?;&%B+GAM;,5=76_;.!9][Z_09K' #C!L1(FB
MR&+:02;M#(K)M-TF@QELL3#XF0BUK4!6VO3?+RG;B1U)-DG9ZDOB.-0]/-<^
M.I>D1/WT\_UL&GU1U:(HYR]/X//X)%)S4<IB?OWRY,^K7P$Y^?G5LV<__0.
MOW_Y>!&]+L7=3,WKZ+Q2K%8R^EK4-U%]HZ*_RNIS\85%'Z:LUF4U ^!5<]AY
M>?NM*JYOZBB)$[1NMOYO]4+G-(%ISH%6* 8HQ0PP@>R?$,(TE;E*DA^O7Q#)
M4LX% K%F"4 :QX"1/ =*XR060A.D\B;HM)A_?F%_<+90D:$W7S1_OCRYJ>O;
M%Z>G7[]^?7[/J^GSLKH^3>(X/5VW/EDUOV^U_YHVK2&E]+3Y[T/31='5T(2%
MIW__<7$I;M2,@6*^J-E<6(!%\6+1O'E1"E8W6=_;KZBWA?T+K)L!^Q: "4CA
M\_N%/'GU+(J6Z:C*J?JH=&1___GQ;2\D/;4M3N?JVGZV'U15E/*R9E5]P;B:
MFMXWT>IOM^KER:*8W4[5^KV;2NGNL-.JVHIJ>TEM+R&VO?QG']CI@.X?J+]U
MNZ\'Z%Q#]]VA^K@KI^\.UMTK<X90Q^_P!LS@+B^_4&_F<JSO[@/4X*X?O\>'
M^EJ4-9N.\+5XA-GH\M2^<6%>K6!LH!TGTP9G=>K>Z*JZK]5<JN79<BMT5,B7
M)^;5Y&X!KAF[G9Q/V6+Q7E_6I?C\NIRQ8CY)I#+6Q2!@B4P!(D@"JI0 7!)!
MN! T96I2/WRK)VH._KQ<=Z!!V0=QXL&N[E%II1;E7266_F9@K;<O>_*J 8Q*
M'360T:<EZ/]^.GWL85!BIB/0G1Z5:2FV(D^M79?54S*E<"#S*("%8=,PT6S!
M&SJKHT]M<72JIO5B_0ZP[S0JV %PVOIPSJIUOUDE]F1QU>)4E*8VN:W!5D)U
M5<Y<"=:EZ^>Z3*8!/HG*2JK*U)P=)!Z^85(5DS?SNJB_O355:75;5DW-9,J$
M6IV7=_.Z^G9>2C5)4*(81#G ,"$ \50"@E,,",DD92@F(B<N.G3$.[(HESV(
MMKKP8]1TPF0M6G4DLCUQ$ZIK&G>K]@C)\9/P(?+B+&M/MAT:7RCQ_+K\<FHB
M+>5M7CRJVC7^*!+W)+O6N^]A@>(OU.**\:F:2*)T'C,">)J;0:!*&: R2P!F
M.8HSSDCF9K>MR&,(VF!%GQHT1WMM\W?49PBK "6Z$/*7V]/.APOK(=*X$GI*
MH"665H-03[PH%G4QOUZ\N1<WYM-19_?%8I(CS!6$VDZE"&.%Y@?/:0Y2G7.M
M4Y7E./&SPBZ8<1QPC?QCM,:./EET7P%U9\K5[8;R#S(Y?^H!SK:+V0!#ZPP[
MLH_MHM:VKYVM_>2YKH$;$[13I9O%</.]PY@82LSHDN34*)0D@$)BAH^00ZQ0
MS'/L5*SN11IY[.BAS/U)<AM 'H3ZL''D@43IS.A @\E^G%''E'OI/AU:[C_
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MPHXFQOW4-B7IT-I/F&QV/9^<)<_C^%+-B[)Z5]9J\?I.F3SAU9P9)%K#'!*
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M:M,S\^I1(8\Q1I%&J\MK3;3_T2>&S;P9+_G\ZMGZG6+Y5-)7S_X/4$L#!!0
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M<F5L96$N:'1M4$L! A0#%     @ P8!>6<N15@0Y&   ]ZD  !$
M     ( !;X8  &%M9VXM,C R-#$P,S N:'1M4$L! A0#%     @ P8!>65J&
M-S)( P  E L  !$              ( !UYX  &%M9VXM,C R-#$P,S N>'-D
M4$L! A0#%     @ P8!>69PW&I4B"0  8$,  !4              ( !3J(
M &%M9VXM,C R-#$P,S!?9&5F+GAM;%!+ 0(4 Q0    ( ,& 7EGQ$C.QQ T
M &5V   5              "  :.K  !A;6=N+3(P,C0Q,#,P7VQA8BYX;6Q0
M2P$"% ,4    " #!@%Y9W#>-C+0(  "_1   %0              @ &:N0
K86UG;BTR,#(T,3 S,%]P<F4N>&UL4$L%!@     &  8 DP$  ('"      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>amgn-20241030_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amgn="http://www.amgen.com/20241030"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:exch="http://xbrl.sec.gov/exch/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amgn-20241030.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2024-10-30</startDate>
            <endDate>2024-10-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-30</startDate>
            <endDate>2024-10-30</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-30</startDate>
            <endDate>2024-10-30</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-24">0000318154</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-25">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-10-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Amgen Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37702</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">91320-1799</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">805</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">447-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-17">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-18">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-20">2.000% Senior Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-21">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-26">2024-10-30</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-27">2024-10-30</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
